Randomized Trial of Benznidazole for Chronic Chagasâ

New England Journal of Medicine 373, 1295-1306 DOI: 10.1056/nejmoa1507574

Citation Report

IF ARTICLE CITATIONS Chagas Disease., 0,, 44-51. 0 1 Developments in the management of Chagas cardiomyopathy. Expert Review of Cardiovascular Therapy, 1.5 2015, 13, 1393-1409. Immunity and immune modulation in <i>Trypanosoma cruzi</i>infection. Pathogens and Disease, 2015, 3 2.0 75 73, ftv082. Treatment of Chagas' Disease â€" Time Is Running Out. New England Journal of Medicine, 2015, 373, 29 1369-1370. Benznidazole therapy for Chagas disease in asymptomatic Trypanosoma cruzi -seropositive former blood donors: evaluation of the efficacy of different treatment regimens. Revista Da Sociedade 5 0.9 11 Brasileira De Medicina Tropical, 2016, 49, 713-720. Ocular Parasitic Infections – An Overview. , 2016, , . Chagas Heart Failure in Patients from Latin America. Cardiac Failure Review, 2016, 2, 90-94. 7 3.0 9 Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a 1.6 36 new formulation of benznidazole. Memorias Do Instituto Oswaldo Cruz, 2016, 111, 218-221. Serological based monitoring of a cohort of patients with chronic Chagas disease treated with 9 benznidazole in a highly endemic area of northern Argentina. Memorias Do Instituto Oswaldo Cruz, 12 1.6 2016, 111, 365-371. High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala. Revista Da Sociedade Brasileira De Medicina Tropical, 2016, 49, 721-727. Chronic Chagas' Disease: Targeting the Interleukin-2 Axis and Regulatory T Cells in a Condition for 11 3.55 Which There Is No Treatment. Frontiers in Microbiology, 2016, 7, 675. The BENEFIT Trial: Where Do We Go from Here?. PLoS Neglected Tropical Diseases, 2016, 10, e0004343. 3.0 2 nd Brazilian Consensus on Chagas Disease, 2015. Revista Da Sociedade Brasileira De Medicina Tropical, 13 0.9 239 2016, 49, 3-60. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period. Recent 14 0.8 Patents on Anti-infective Drug Discovery, 2016, 11, 74-173. Quantification by real-time PCR of Trypanosoma cruzi DNA in samples of Triatoma infestans used in 2.513 16 xenodiagnosis of chronic Chagas disease patients. Parasites and Vectors, 2016, 9, 382. Contemporary clinical trial updates in heart failure. Current Opinion in Cardiology, 2016, 31, 349-355. 1.8 Chronic Chagas disease: can prophylaxis and therapeutic vaccines crack this â€⁻hard nutâ€[™]?. 18 2.0 1 Immunotherapy, 2016, 8, 99-101. Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a 19 44 cohort profile. BMJ Open, 2016, 6, e011181.

#	Article	IF	CITATIONS
20	The TcTASV proteins are novel promising antigens to detect active <i>Trypanosoma cruzi</i> infection in dogs. Parasitology, 2016, 143, 1382-1389.	1.5	7
21	Interpreting Geographic Variations in Results of Randomized, Controlled Trials. New England Journal of Medicine, 2016, 375, 2263-2271.	27.0	71
22	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles. European Journal of Medicinal Chemistry, 2016, 115, 295-310.	5.5	29
23	Apoptotic CD8 T-lymphocytes disable macrophage-mediated immunity to Trypanosoma cruzi infection. Cell Death and Disease, 2016, 7, e2232-e2232.	6.3	20
24	Chagas cardiomyopathy: The potential effect of benznidazole treatment on diastolic dysfunction and cardiac damage in dogs chronically infected with Trypanosoma cruzi. Acta Tropica, 2016, 161, 44-54.	2.0	29
25	Chagas' disease in Aboriginal and Creole communities from the Gran Chaco Region of Argentina: Seroprevalence and molecular parasitological characterization. Infection, Genetics and Evolution, 2016, 41, 84-92.	2.3	28
26	Pupillary Light Reflexes are Associated with Autonomic Dysfunction in Bolivian Diabetics But Not Chagas Disease Patients. American Journal of Tropical Medicine and Hygiene, 2016, 94, 1290-1298.	1.4	3
27	Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 3700-3708.	3.2	22
28	Status of vaccine research and development of vaccines for Chagas disease. Vaccine, 2016, 34, 2996-3000.	3.8	56
29	Antiparasitic evaluation of betulinic acid derivatives reveals effective and selective anti-Trypanosoma cruzi inhibitors. Experimental Parasitology, 2016, 166, 108-115.	1.2	33
30	Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease. International Journal of Antimicrobial Agents, 2016, 48, 91-95.	2.5	26
31	Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 4297-4309.	3.2	48
32	Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease. Acta Tropica, 2016, 164, 117-124.	2.0	29
33	Predominance of Th1 response, increase of megakaryocytes and Kupffer cells are related to survival in Trypanosoma cruzi infected mice treated with Lycopodium clavatum. Cytokine, 2016, 88, 57-61.	3.2	12
34	Interactions between 4-aminoquinoline and heme: Promising mechanism against Trypanosoma cruzi. International Journal for Parasitology: Drugs and Drug Resistance, 2016, 6, 154-164.	3.4	17
35	Putting Infection Dynamics at the Heart of Chagas Disease. Trends in Parasitology, 2016, 32, 899-911.	3.3	83
36	Quantitative PCR and unconventional serological methods to evaluate clomipramine treatment effectiveness in experimental Trypanosoma cruzi infection. Experimental and Molecular Pathology, 2016, 101, 274-280.	2.1	4
37	Pentamidine antagonizes the benznidazole's effect inÂvitro, and lacks of synergy inÂvivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target. Experimental Parasitology, 2016, 171. 23-32.	1.2	13

#	Article	IF	CITATIONS
38	The changing face of cardiovascular disease 2000–2012: An analysis of the world health organisation global health estimates data. International Journal of Cardiology, 2016, 224, 256-264.	1.7	197
39	Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature, 2016, 537, 229-233.	27.8	325
41	Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides. Journal of Medicinal Chemistry, 2016, 59, 9686-9720.	6.4	30
42	Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 7035-7042.	3.2	12
43	Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States. Clinical Infectious Diseases, 2016, 63, 1056-1062.	5.8	80
44	Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Scientific Reports, 2016, 6, 35351.	3.3	72
45	Drug resistance in eukaryotic microorganisms. Nature Microbiology, 2016, 1, 16092.	13.3	118
46	Heart Failure Secondary to Chagas Disease: an Emerging Problem in Non-endemic Areas. Current Heart Failure Reports, 2016, 13, 295-301.	3.3	11
47	The year in cardiology 2015: heart failure. European Heart Journal, 2016, 37, 437-441.	2.2	2
48	Benznidazole for Chronic Chagas' Cardiomyopathy. New England Journal of Medicine, 2016, 374, 188-190.	27.0	15
49	Synthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain. ACS Medicinal Chemistry Letters, 2016, 7, 77-82.	2.8	26
50	Plague—Older Than We Knew. Clinical Infectious Diseases, 2016, 62, iii-iv.	5.8	0
51	Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug repositioning. Journal of Computer-Aided Molecular Design, 2016, 30, 305-321.	2.9	39
52	Parasitic diseases of the central nervous system: lessons for clinicians and policy makers. Expert Review of Neurotherapeutics, 2016, 16, 401-414.	2.8	47
53	A therapeutic nanoparticle vaccine against <i>Trypanosoma cruzi</i> in a BALB/c mouse model of Chagas disease. Human Vaccines and Immunotherapeutics, 2016, 12, 976-987.	3.3	52
54	Clinical Cardiology, Geriatric Cardiology, Heart Failure, and Transplantation 2015: A Selection of Topical Issues. Revista Espanola De Cardiologia (English Ed), 2016, 69, 159-166.	0.6	5
56	Selección de temas de actualidad en cardiologÃa clÃnica, cardiologÃa geriátrica e insuficiencia cardiaca y trasplante 2015. Revista Espanola De Cardiologia, 2016, 69, 159-166.	1.2	9
57	Total Artificial Heart as Bridge to Heart Transplantation in Chagas Cardiomyopathy: Case Report. Transplantation Proceedings, 2016, 48, 279-281.	0.6	11

		CITATION R	EPORT	
#	Article		IF	CITATIONS
58	Epidemiology and aetiology of heart failure. Nature Reviews Cardiology, 2016, 13, 368	-378.	13.7	1,181
59	Novel drug discovery for Chagas disease. Expert Opinion on Drug Discovery, 2016, 11,	447-455.	5.0	18
60	Clinical Candidate VT-1161's Antiparasitic Effect <i>In Vitro</i> , Activity in a Murine M Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 fro cruzi. Antimicrobial Agents and Chemotherapy, 2016, 60, 1058-1066.	Iodel of Chagas om Trypanosoma	3.2	34
61	Ruthenium(II) complexes of 1,3-thiazolidine-2-thione: Cytotoxicity against tumor cells a anti-Trypanosoma cruzi activity enhanced upon combination with benznidazole. Journa Biochemistry, 2016, 156, 153-163.	and al of Inorganic	3.5	48
62	Better results from prevention than from additional treatment. Nature Reviews Cardiol 75-77.	ogy, 2016, 13,	13.7	2
63	Current drug therapy and pharmaceutical challenges for Chagas disease. Acta Tropica,	2016, 156, 1-16.	2.0	203
64	Acute Chagas Disease and Risk of Congenital Infection. Clinical Infectious Diseases, 20	16, 62, 407-408.	5.8	1
65	Carbonic anhydrases from Trypanosoma and Leishmania as anti-protozoan drug target and Medicinal Chemistry, 2017, 25, 1543-1555.	s. Bioorganic	3.0	52
66	Valor diagnóstico del NT-proBNP para la detección precoz deÂcardiopatÃa chagásic noÂendémicas. Revista Espanola De Cardiologia, 2017, 70, 783-785.	a enÂÃ;reas	1.2	1
67	Chagas disease research and development: Is there light at the end of the tunnel?. Con Structural Biotechnology Journal, 2017, 15, 98-103.	nputational and	4.1	111
68	Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cru rhodesain designed by molecular simplification. Bioorganic and Medicinal Chemistry, 2 1889-1900.	ızain and 017, 25,	3.0	39
69	Antitrypanosomal and antileishmanial activity of prenyl-1,2,3-triazoles. MedChemComi 1015-1021.	m, 2017, 8,	3.4	20
70	Cardiac manifestations of parasitic diseases. Heart, 2017, 103, 651-658.		2.9	62
71	Benznidazole and Posaconazole inÂEliminating Parasites in Asymptomatic T.ÂCruzi C the American College of Cardiology, 2017, 69, 939-947.	arriers. Journal of	2.8	231
72	A New Epoch in Antitrypanosomal Treatment for Chagas Disease â^—. Journal of the Ar Cardiology, 2017, 69, 948-950.	nerican College of	2.8	7
73	Diagnostic Value of NT-proBNP for Early Identification of Chagas Cardiomyopathy in No Areas. Revista Espanola De Cardiologia (English Ed), 2017, 70, 783-785.	on-endemic	0.6	1
74	Cost-effectiveness of Chagas disease screening in Latin American migrants at primary l centres in Europe: a Markov model analysis. The Lancet Global Health, 2017, 5, e439-e	nealth-care 447.	6.3	84
75	Antiparasitic Treatment Induces an Improved CD8+ T Cell Response in Chronic Chagas Journal of Immunology, 2017, 198, 3170-3180.	ic Patients.	0.8	43

#	Article	IF	CITATIONS
76	Challenges in the management of Chagas disease in Latin-American migrants in Europe. Clinical Microbiology and Infection, 2017, 23, 290-295.	6.0	61
77	Prevalence of Chagas Disease in the Latin American–born Population of Los Angeles. Clinical Infectious Diseases, 2017, 64, 1182-1188.	5.8	94
78	Autochthonous Chagas disease in the southern United States: A case report of suspected residential and military exposures. Zoonoses and Public Health, 2017, 64, 491-493.	2.2	14
79	Chagas disease in Europe: A review for the internist in the globalized world. European Journal of Internal Medicine, 2017, 43, 6-15.	2.2	148
80	Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease. Journal of Antimicrobial Chemotherapy, 2017, 72, 2596-2601.	3.0	31
81	Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases. ChemMedChem, 2017, 12, 1235-1253.	3.2	26
82	Abnormal 18F-FDG and 82Rb PET Findings in Chagas Heart Disease. Clinical Nuclear Medicine, 2017, 42, e265-e268.	1.3	6
83	Trans-sialidase overcomes many antigens to be used as a vaccine candidate against <i>Trypanosoma cruzi</i> . Immunotherapy, 2017, 9, 555-565.	2.0	16
84	Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status. BMC Infectious Diseases, 2017, 17, 221.	2.9	21
85	Chagas disease immunogenetics: elusive markers of disease progression. Expert Review of Cardiovascular Therapy, 2017, 15, 367-376.	1.5	7
86	An inÂvitro and inÂvivo evaluation of new potential trans -sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method. European Journal of Medicinal Chemistry, 2017, 132, 249-261.	5.5	38
87	Treatment of Chagas disease. , 2017, , 751-771.		6
88	Association of Cardiac Galectin-3 Expression, Myocarditis, and Fibrosis in Chronic Chagas Disease Cardiomyopathy. American Journal of Pathology, 2017, 187, 1134-1146.	3.8	43
89	Blood Gene Signatures of Chagas Cardiomyopathy With or Without Ventricular Dysfunction. Journal of Infectious Diseases, 2017, 215, 387-395.	4.0	32
90	Simvastatin Attenuates Endothelial Activation through 15-Epi-Lipoxin A4 Production in Murine Chronic Chagas Cardiomyopathy. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	27
91	Gene Expression Profiling and Functional Characterization of Macrophages in Response to Circulatory Microparticles Produced during <i>Trypanosoma cruzi</i> Infection and Chagas Disease. Journal of Innate Immunity, 2017, 9, 203-216.	3.8	36
92	How universal is coverage and access to diagnosis and treatment for Chagas disease in Colombia? A health systems analysis. Social Science and Medicine, 2017, 175, 187-198.	3.8	40

#	Article	IF	CITATIONS
94	Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole. Scientific Reports, 2017, 7, 14407.	3.3	41
95	The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease. Journal of Clinical Microbiology, 2017, 55, 3444-3453.	3.9	16
96	Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 378-387.	3.4	19
97	Biological factors that impinge on Chagas disease drug development. Parasitology, 2017, 144, 1871-1880.	1.5	45
98	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against <i>Trypanosoma cruzi</i> . Journal of Medicinal Chemistry, 2017, 60, 7284-7299.	6.4	31
99	Inflammatory Cardiomyopathic Syndromes. Circulation Research, 2017, 121, 803-818.	4.5	213
100	Cell therapies for Chagas disease. Cytotherapy, 2017, 19, 1339-1349.	0.7	10
101	Chronic Chagas Heart DiseaseÂManagement. Journal of the American College of Cardiology, 2017, 70, 1510-1524.	2.8	138
102	Pharmacist intervention in patients receiving treatment for Chagas disease: An emerging challenge for non-endemic countries. Infection, Disease and Health, 2017, 22, 219-226.	1.1	2
103	<i>Strongyloides stercoralis</i> infection increases the likelihood to detect <i>Trypanosoma cruzi </i> <scp>DNA</scp> in peripheral blood in Chagas disease patients. Tropical Medicine and International Health, 2017, 22, 1436-1441.	2.3	16
104	Addressing the Challenges of Chagas Disease. Infectious Diseases in Clinical Practice, 2017, 25, 118-125.	0.3	14
105	In silico, in vitro, X-ray crystallography, and integrated strategies for discovering spermidine synthase inhibitors for Chagas disease. Scientific Reports, 2017, 7, 6666.	3.3	21
106	Anti-parasitic effect of novel amidines against Trypanosoma cruzi: phenotypic and in silico absorption, distribution, metabolism, excretion and toxicity analysis. Parasitology Open, 2017, 3, .	0.9	5
107	Congenitally transmitted Chagas disease in Canada: a family cluster. Cmaj, 2017, 189, E1489-E1492.	2.0	8
108	Heart transplantation for Chagas cardiomyopathy. Revista Portuguesa De Cardiologia, 2017, 36, 871.e1-871.e4.	0.5	7
109	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	3.9	53
110	Tropical Parasitic Infections in Individuals Infected With HIV. Current Tropical Medicine Reports, 2017, 4, 268-280.	3.7	3
111	Increased of the hepatocytes and splenocytes apoptosis accompanies clinical improvement and higher survival in mice infected with Trypanosoma cruzi and treated with highly diluted Lycopodium clavatum. Microbial Pathogenesis, 2017, 110, 107-116.	2.9	4

#		IF	CITATIONS
π	Inflammation in Heart Failure: known knowns and unknown unknowns. Expert Opinion on	10	22
112	Pharmacotherapy, 2017, 18, 1225-1233.	1.8	23
113	Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy. Infection and Immunity, 2017, 85, .	2.2	16
114	Pharmacodynamics and Follow-Up Period in the Treatment of Human Trypanosoma Cruzi Infections With Posaconazole. Journal of the American College of Cardiology, 2017, 70, 299-300.	2.8	17
115	Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Human Vaccines and Immunotherapeutics, 2017, 13, 621-633.	3.3	39
116	Chagas Disease (American Trypanosomiasis). , 2017, , 1065-1072.e1.		2
117	Overcoming research barriers in Chagas disease—designing effective implementation science. Parasitology Research, 2017, 116, 35-44.	1.6	8
118	Editorial commentary: Targeting Chagas disease. Trends in Cardiovascular Medicine, 2017, 27, 92-94.	4.9	0
119	Chagas Cardiomyopathy. Cardiology Clinics, 2017, 35, 31-47.	2.2	77
120	Neglected tropical diseases: progress towards addressing the chronic pandemic. Lancet, The, 2017, 389, 312-325.	13.7	252
121	Heart transplantation for Chagas cardiomyopathy. Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.784	4314 rgBT 0.2	/Oyerlock 10
122	Novel Insights into the Pathophysiology of Chagas' Cardiomyopathy. , 2017, , .		1
123	Increasing access to comprehensive care for Chagas disease: development of a patient-centered model in Colombia. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2017, 41, 1-9.	1.1	12
124	Chagas Disease-induced Sudden Cardiac Arrest. Clinical Practice and Cases in Emergency Medicine, 2017, 1, 354-358.	0.3	2
125	Biosensors to Diagnose Chagas Disease: A Brief Review. Sensors, 2017, 17, 2629.	3.8	11
126	History of the discovery of the American Trypanosomiasis (Chagas disease). , 2017, , 1-22.		5
127	Analytical sensitivity and specificity of a loop-mediated isothermal amplification (LAMP) kit prototype for detection of Trypanosoma cruzi DNA in human blood samples. PLoS Neglected Tropical Diseases, 2017, 11, e0005779.	3.0	69
128	Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 296-300.	0.9	57
129	Protozoan Diseases: Chagas Disease. , 2017, , 70-78.		0

#	Article	IF	CITATIONS
130	Mast Cell Coupling to the Kallikrein–Kinin System Fuels Intracardiac Parasitism and Worsens Heart Pathology in Experimental Chagas Disease. Frontiers in Immunology, 2017, 8, 840.	4.8	25
131	Chagas Cardiomyopathy Presenting as Symptomatic Bradycardia: An Underappreciated Emerging Public Health Problem in the United States. Case Reports in Cardiology, 2017, 2017, 1-5.	0.2	2
132	Potential Role of Carvedilol in the Cardiac Immune Response Induced by Experimental Infection with Trypanosoma cruzi. BioMed Research International, 2017, 2017, 1-7.	1.9	7
133	Mutagenic and Cytotoxicity LQB 123 Profile: Safety and Tripanocidal Effect of a Phenyl-t-Butylnitrone Derivative. BioMed Research International, 2017, 2017, 1-8.	1.9	1
134	Sexual transmission of American trypanosomiasis in humans: a new potential pandemic route for Chagas parasites. Memorias Do Instituto Oswaldo Cruz, 2017, 112, 437-446.	1.6	17
135	Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. Memorias Do Instituto Oswaldo Cruz, 2017, 112, 224-235.	1.6	152
136	Association of caspase-1 polymorphisms with Chagas cardiomyopathy among individuals in Santa Cruz, Bolivia. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 516-523.	0.9	6
137	Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole: drug-related problems and pharmaceutical interventions. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 334-340.	0.9	3
138	Experimental and Clinical Treatment of Chagas Disease: A Review. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1289-1303.	1.4	212
139	Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. PLoS ONE, 2017, 12, e0185033.	2.5	44
140	4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection. PLoS Neglected Tropical Diseases, 2017, 11, e0006132.	3.0	24
141	Access to benznidazole for Chagas disease in the United States—Cautious optimism?. PLoS Neglected Tropical Diseases, 2017, 11, e0005794.	3.0	23
142	Ten years of Chagas disease research: Looking back to achievements, looking ahead to challenges. PLoS Neglected Tropical Diseases, 2017, 11, e0005422.	3.0	24
143	An ImmunoSignature test distinguishes Trypanosoma cruzi, hepatitis B, hepatitis C and West Nile virus seropositivity among asymptomatic blood donors. PLoS Neglected Tropical Diseases, 2017, 11, e0005882.	3.0	12
144	Combined parasitological and molecular-based diagnostic tools improve the detection of Trypanosoma cruzi in single peripheral blood samples from patients with Chagas disease. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 506-515.	0.9	8
145	Therapeutic drug monitoring of benznidazole and nifurtimox: a systematic review and quality assessment of published clinical practice guidelines. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 748-755.	0.9	20
146	Chagas Cardiomyopathy. , 2017, , 553-574.		1
147	Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection. Drug Design, Development and Therapy, 2017, Volume11, 1095-1105.	4.3	8

#	Article	IF	CITATIONS
149	Molecular diagnostics for Chagas disease: up to date and novel methodologies. Expert Review of Molecular Diagnostics, 2017, 17, 699-710.	3.1	37
150	Chronic Chagas cardiomyopathy: a therapeutic challenge and future strategies. Emerging Topics in Life Sciences, 2017, 1, 579-584.	2.6	0
151	Antiparasitic Agents. , 2017, , 717-750.		0
152	Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1469-1476.	1.4	30
153	Trans-sialidase-based vaccine candidate protects against <i>Trypanosoma cruzi</i> infection, not only inducing an effector immune response but also affecting cells with regulatory/suppressor phenotype. Oncotarget, 2017, 8, 58003-58020.	1.8	23
154	Molecular diagnosis of Trypanosoma cruzi. Acta Tropica, 2018, 184, 59-66.	2.0	76
155	Temporal trends in the contribution of Chagas cardiomyopathy to mortality among patients with heart failure. Heart, 2018, 104, 1522-1528.	2.9	17
156	Challenges of immunosuppressive and antitrypanosomal drug therapy after heart transplantation in patients with chronic Chagas disease: A systematic review of clinical recommendations. Transplantation Reviews, 2018, 32, 157-167.	2.9	22
157	InÂvitro and inÂvivo drug combination for the treatment of Trypanosoma cruzi infection: A multivariate approach. Experimental Parasitology, 2018, 189, 19-27.	1.2	12
158	Comparison of parasite loads in serum and blood samples from patients in acute and chronic phases of Chagas disease. Parasitology, 2018, 145, 1837-1843.	1.5	11
159	What makes an effective Chagas disease vector? Factors underlying Trypanosoma cruzi-triatomine interactions. Acta Tropica, 2018, 183, 23-31.	2.0	75
160	Anti-Trypanosoma cruzi action of a new benzofuran derivative based on amiodarone structure. Experimental Parasitology, 2018, 189, 8-15.	1.2	16
161	Targeting polyamine transport in Trypanosoma cruzi. European Journal of Medicinal Chemistry, 2018, 147, 1-6.	5.5	20
162	Antiparasitic Agents. , 2018, , 1567-1587.e2.		6
163	Challenges and opportunities in the vertical transmission of Chagas disease. Anales De PediatrÃa (English Edition), 2018, 88, 119-121.	0.2	0
165	Identification of cisapride as new inhibitor of putrescine uptake in Trypanosoma cruzi by combined ligand- and structure-based virtual screening. European Journal of Medicinal Chemistry, 2018, 149, 22-29.	5.5	15
166	Chagas Disease Recommendations for Solid-Organ Transplant Recipients and Donors. Transplantation, 2018, 102, S1-S7.	1.0	41
167	Comment on: Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease. Journal of Antimicrobial Chemotherapy, 2018, 73, 1114-1115	3.0	1

#	Article	IF	CITATIONS
168	Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infectious Diseases, The, 2018, 18, 419-430.	9.1	214
169	Pathogenesis of Chronic Chagas Disease: Macrophages, Mitochondria, and Oxidative Stress. Current Clinical Microbiology Reports, 2018, 5, 45-54.	3.4	51
170	Identification of Anti-Trypanosoma cruzi Lead Compounds with Putative Immunomodulatory Activity. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
171	The long road towards a safe and effective treatment of chronic Chagas disease. Lancet Infectious Diseases, The, 2018, 18, 363-365.	9.1	28
172	What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. Journal of Antimicrobial Chemotherapy, 2018, 73, 1060-1067.	3.0	57
173	Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a <i>post hoc</i> analysis of the SHIFT trial. ESC Heart Failure, 2018, 5, 249-256.	3.1	20
174	Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. Journal of Pharmaceutical Sciences, 2018, 107, 1468-1473.	3.3	23
175	Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease. Infection and Immunity, 2018, 86, .	2.2	47
176	Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease—authors' response. Journal of Antimicrobial Chemotherapy, 2018, 73, 1115-1116.	3.0	2
177	Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2018-2022.	2.2	6
178	Trypanosoma cruzi infection of human induced pluripotent stem cell-derived cardiomyocytes: an inAvitro model for drug screening forÂChagas disease. Microbes and Infection, 2018, 20, 312-316.	1.9	17
179	Chagas disease knocks on our door: a cross-sectional study among Latin American immigrants in Milan, Italy. Clinical Microbiology and Infection, 2018, 24, 1340.e1-1340.e6.	6.0	13
180	Investigation of the binding mode of a novel cruzain inhibitor by docking, molecular dynamics, ab initio and MM/PBSA calculations. Journal of Computer-Aided Molecular Design, 2018, 32, 591-605.	2.9	18
181	Chagas disease. Lancet, The, 2018, 391, 82-94.	13.7	945
182	Predictors of death in chronic Chagas cardiomyopathy patients with pacemaker. International Journal of Cardiology, 2018, 250, 260-265.	1.7	7
183	Progressive Conduction System Disease. , 2018, , 996-1002.		0
184	Acquired heart disease in low-income and middle-income countries. Archives of Disease in Childhood, 2018, 103, 73-77.	1.9	13
185	Phenotypic screening approaches for Chagas disease drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 141-153.	5.0	68

#	Article	IF	CITATIONS
186	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound. European Journal of Medicinal Chemistry, 2018, 144, 572-581.	5.5	36
187	<i>In Vitro</i> and <i>In Vivo</i> Studies of the Trypanocidal Effect of Novel Quinolines. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
188	From Lemongrass to Ivermectin: Ethnomedical Management of Chagas Disease in Tropical Bolivia. Medical Anthropology: Cross Cultural Studies in Health and Illness, 2018, 37, 236-252.	1.2	15
189	Severe immune thrombocytopaenia in a patient taking benznidazole for chronic Chagas disease. BMJ Case Reports, 2018, 2018, bcr-2017-223788.	0.5	2
190	New Approaches for Chagas' Disease Chemotherapy. , 0, , .		1
191	Efficacy and Safety of Chagas Disease Drug Therapy and Treatment Perspectives. , 0, , .		6
192	Novel Physiotherapies in the Setting of Chagas Heart Disease: A Summarized Review of Functional Evaluation. Journal of Novel Physiotherapies, 2018, 08, .	0.1	0
193	Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2018, 24, 30.	1.4	16
194	Archaea Symbiont of T. cruzi Infection May Explain Heart Failure in Chagas Disease. Frontiers in Cellular and Infection Microbiology, 2018, 8, 412.	3.9	5
195	Phylogeography and demographic history of the Chagas disease vector Rhodnius nasutus (Hemiptera:) Tj ETQq1	1 0.78431	l4 rgBT /Ove
196	Continuing evidence of Chagas disease along the Texas-Mexico border. PLoS Neglected Tropical Diseases, 2018, 12, e0006899.	3.0	10
197	The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission. PLoS Neglected Tropical Diseases, 2018, 12, e0006809.	3.0	32
198	¿Quién se beneficia actualmente del tratamiento etiológico de la enfermedad de Chagas?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 395-396.	0.5	1
199	Assessment of syndecan-4 expression in the hearts of Trypanosoma cruzi-infected mice and human subjects with chronic Chagas disease cardiomyopathy. Surgical and Experimental Pathology, 2018, 1, .	0.6	2
200	Electrocardiographic alterations and cardiomegaly in a Bolivian migrant. Journal of Travel Medicine, 2018, 25, .	3.0	2
201	Correlation of transforming growth factor-β1 and tumour necrosis factor levels with left ventricular function in Chagas disease. Memorias Do Instituto Oswaldo Cruz, 2018, 113, e170440.	1.6	10
202	La respuesta inmunitaria adaptativa en la infección crónica por Trypanosoma cruzi. Revista De La Academia Colombiana De Ciencias Exactas, Fisicas Y Naturales, 2018, 41, 456.	0.2	2
203	Conserved epitopes in variants of amastin protein of Trypanosoma cruzi for vaccine design: A bioinformatics approach. Microbial Pathogenesis, 2018, 125, 423-430.	2.9	5

#	Article	IF	CITATIONS
204	Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study. PLoS Neglected Tropical Diseases, 2018, 12, e0006814.	3.0	59
205	Diagnosis and Management of Chagas Cardiomyopathy in the United States. Current Cardiology Reports, 2018, 20, 131.	2.9	13
206	Synthesis, in vitro and in vivo anti-Trypanosoma cruzi and toxicological activities of nitroaromatic Schiff bases. Biomedicine and Pharmacotherapy, 2018, 108, 1703-1711.	5.6	17
207	Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: Reduced intensity of tissue parasitism and inflammation—A histopathological study. International Journal of Experimental Pathology, 2018, 99, 236-248.	1.3	13
208	Cardiac surgery for Chagas disease. Journal of Cardiac Surgery, 2018, 33, 597-602.	0.7	3
209	Phenotypic diversity and drug susceptibility of Trypanosoma cruzi TcV clinical isolates. PLoS ONE, 2018, 13, e0203462.	2.5	20
210	Sociocultural dynamics that influence Chagas disease health care in Colombia. Social Science and Medicine, 2018, 215, 142-150.	3.8	17
211	Signaling Pathways Targeted by Protozoan Parasites to Inhibit Apoptosis. , 2018, , .		2
212	Reduced functional capacity in patients with Chagas disease: a systematic review with meta-analysis. Revista Da Sociedade Brasileira De Medicina Tropical, 2018, 51, 421-426.	0.9	18
213	Implantable cardioverter-defibrillator in Chagas heart disease: A systematic review and meta-analysis of observational studies. International Journal of Cardiology, 2018, 267, 88-93.	1.7	11
214	Chagas Cardiomyopathy: A Comprehensive Perioperative Review. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 2780-2788.	1.3	3
215	Chagas Cardiomyopathy: Evidence in Medical and Nutritional Management. Current Tropical Medicine Reports, 2018, 5, 193-203.	3.7	0
216	Treatment of Chagas Disease in the United States. Current Treatment Options in Infectious Diseases, 2018, 10, 373-388.	1.9	74
217	ROS and Trypanosoma cruzi: Fuel to infection, poison to the heart. PLoS Pathogens, 2018, 14, e1006928.	4.7	91
218	Parasitosis con manifestaciones clÃnicas neurológicas y cardÃacas. Medicine, 2018, 12, 3416-3421.	0.0	0
219	Autoimmunity and theÂParadox of Chagas Disease. , 2018, , 139-147.		1
220	Current advances in drug discovery for Chagas disease. European Journal of Medicinal Chemistry, 2018, 155, 824-838.	5.5	70
221	Scientometrics analysis of research activity and collaboration patterns in Chagas cardiomyopathy. PLoS Neglected Tropical Diseases, 2018, 12, e0006602.	3.0	24

#	Article	IF	CITATIONS
222	Induction of programmed cell death in Trypanosoma cruzi by Lippia alba essential oils and their major and synergistic terpenes (citral, limonene and caryophyllene oxide). BMC Complementary and Alternative Medicine, 2018, 18, 225.	3.7	32
223	Intersection of phosphate transport, oxidative stress and TOR signalling in Candida albicans virulence. PLoS Pathogens, 2018, 14, e1007076.	4.7	54
224	Hepatic changes by benznidazole in a specific treatment for Chagas disease. PLoS ONE, 2018, 13, e0200707.	2.5	11
225	Who currently benefits from the aetiological treatment for Chagas disease?. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 395-396.	0.3	0
226	Evaluation of in vitro anti-Trypanosoma cruzi activity of medications benznidazole, amiodarone hydrochloride, and their combination. Revista Da Sociedade Brasileira De Medicina Tropical, 2018, 51, 52-56.	0.9	11
227	Chronic Infections of the Heart. , 2018, , 593-599.		0
228	Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds Inhibiting Putrescine Uptake. Frontiers in Cellular and Infection Microbiology, 2018, 8, 173.	3.9	22
229	Programmed Cell Death Protein 1–PDL1 Interaction Prevents Heart Damage in Chronic Trypanosoma cruzi Infection. Frontiers in Immunology, 2018, 9, 997.	4.8	19
230	Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail. Clinical Microbiology and Infection, 2018, 24, 1344.e1-1344.e4.	6.0	24
231	Benefits of Ascorbic Acid in Association with Low-Dose Benznidazole in Treatment of Chagas Disease. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
232	Stress-Induced Proliferation and Cell Cycle Plasticity of Intracellular <i>Trypanosoma cruzi</i> Amastigotes. MBio, 2018, 9, .	4.1	51
233	Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery. PLoS Neglected Tropical Diseases, 2018, 12, e0006612.	3.0	76
234	Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis. Drug Safety, 2018, 41, 1035-1048.	3.2	38
235	Clinical and pharmacological profile of benznidazole for treatment of Chagas disease. Expert Review of Clinical Pharmacology, 2018, 11, 943-957.	3.1	84
236	Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review. Revista Da Sociedade Brasileira De Medicina Tropical, 2018, 51, 133-140.	0.9	5
237	Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circulation, 2018, 138, e169-e209.	1.6	315
238	Course of serological tests in treated subjects with chronic Trypanosoma cruzi infection: A systematic review and meta-analysis of individual participant data. International Journal of Infectious Diseases, 2018, 73, 93-101.	3.3	27
239	Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease. Antimicrobial Agents and Chemotherapy, 2018, 62,	3.2	22

#	Article	IF	Citations
240	Amiodarone for arrhythmia in patients with Chagas disease: A systematic review and individual patient data meta-analysis. PLoS Neglected Tropical Diseases, 2018, 12, e0006742.	3.0	24
241	Chagas disease cardiomyopathy treatment remains a challenge – Authors' reply. Lancet, The, 2018, 391, 2209-2210.	13.7	19
242	Complementary Paths to Chagas Disease Elimination: The Impact of Combining Vector Control With Etiological Treatment. Clinical Infectious Diseases, 2018, 66, S293-S300.	5.8	20
244	Chagas disease cardiomyopathy treatment remains a challenge. Lancet, The, 2018, 391, 2209.	13.7	8
245	Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease. PLoS Neglected Tropical Diseases, 2018, 12, e0006180.	3.0	10
246	Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine. PLoS Neglected Tropical Diseases, 2018, 12, e0006384.	3.0	26
247	The protein family TcTASV-C is a novel Trypanosoma cruzi virulence factor secreted in extracellular vesicles by trypomastigotes and highly expressed in bloodstream forms. PLoS Neglected Tropical Diseases, 2018, 12, e0006475.	3.0	19
248	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease. European Journal of Medicinal Chemistry, 2019, 182, 111610.	5.5	19
249	Chagas disease: comments on the 2018 PAHO Guidelines for diagnosis and management. Journal of Travel Medicine, 2019, 26, .	3.0	11
250	TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas' heart disease. PLoS Neglected Tropical Diseases, 2019, 13, e0007602.	3.0	64
251	Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials. Acta Tropica, 2019, 199, 105120.	2.0	16
252	Response to`letter to the editor: â€~Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America'´. Expert Review of Anti-Infective Therapy, 2019, 17, 673-675.	4.4	3
253	Letter to the editor: â€~Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America'. Expert Review of Anti-Infective Therapy, 2019, 17, 671-672.	4.4	2
254	Chagas Disease Treatment and Rational Drug Discovery: A Challenge That Remains. Frontiers in Pharmacology, 2019, 10, 873.	3.5	9
255	Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial. Trials, 2019, 20, 431.	1.6	19
256	Identification of Phenylpyrazolone Dimers as a New Class of Anti―Trypanosoma cruzi Agents. ChemMedChem, 2019, 14, 1662-1668.	3.2	2
257	Effect of Fluorination on the Structure and Anti- <i>Trypanosoma cruzy</i> Activity of Oxorhenium(V) Complexes with <i>S</i> , <i>N</i> , <i>S</i> -Tridentate Thiosemicarbazones and Benzoylthioureas. Synthesis and Structures of Technetium(V) Analogues. Inorganic Chemistry, 2019, 58, 10129-10138.	4.0	21
258	Anti-Trypanosoma activity of bioactive metabolites from Photorhabdus luminescens and Xenorhabdus nematophila. Experimental Parasitology, 2019, 204, 107724.	1.2	8

#	Article	IF	CITATIONS
259	Chagas Disease: From Discovery to a Worldwide Health Problem. Frontiers in Public Health, 2019, 7, 166.	2.7	309
260	Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs. Journal of the American Veterinary Medical Association, 2019, 255, 317-329.	0.5	25
261	Clinical Trial Registration and Reporting: Drug Therapy and Prevention of Cardiac-Related Infections. Frontiers in Pharmacology, 2019, 10, 757.	3.5	4
262	Drug discovery for chagas disease: A viewpoint. Acta Tropica, 2019, 198, 105107.	2.0	60
263	Copper complexes and carbon nanotube–copper ferrite-catalyzed benzenoid A-ring selenation of quinones: an efficient method for the synthesis of trypanocidal agents. New Journal of Chemistry, 2019, 43, 13751-13763.	2.8	27
264	Betulinic Acid Derivative BA5, Attenuates Inflammation and Fibrosis in Experimental Chronic Chagas Disease Cardiomyopathy by Inducing IL-10 and M2 Polarization. Frontiers in Immunology, 2019, 10, 1257.	4.8	10
265	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease. European Journal of Medicinal Chemistry, 2019, 184, 111778.	5.5	4
266	Nitroheterocyclic derivatives: privileged scaffold for drug development against Chagas disease. Medicinal Chemistry Research, 2019, 28, 2099-2108.	2.4	14
267	Polymorphisms of <i>CHRNA3</i> and <i>CHRNA5</i> : Head and neck cancer and cigarette consumption intensity in a Brazilian population. Molecular Genetics & amp; Genomic Medicine, 2019, 7, e998.	1.2	6
268	Ventricular arrhythmias in the Chagas disease are not random phenomena: Longâ€ŧerm monitoring in Chagas arrhythmias. Journal of Cardiovascular Electrophysiology, 2019, 30, 2370-2376.	1.7	4
269	Improved Biomarker and Imaging Analysis for Characterizing Progressive Cardiac Fibrosis in a Mouse Model of Chronic Chagasic Cardiomyopathy. Journal of the American Heart Association, 2019, 8, e013365.	3.7	21
270	Sesquiterpene lactone potentiates the immunomodulatory, antiparasitic and cardioprotective effects on anti-Trypanosoma cruzi specific chemotherapy. International Immunopharmacology, 2019, 77, 105961.	3.8	19
271	In Vitro Benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma cruzi Strains Belonging to Discrete Typing Units TcI, TcII, and TcV. Pathogens, 2019, 8, 197.	2.8	26
273	Metabolomics, lipidomics and proteomics profiling of myoblasts infected with Trypanosoma cruzi after treatment with different drugs against Chagas disease. Metabolomics, 2019, 15, 117.	3.0	11
274	An evaluation of benznidazole as a Chagas disease therapeutic. Expert Opinion on Pharmacotherapy, 2019, 20, 1797-1807.	1.8	32
275	Chagas Disease. Birkhauser Advances in Infectious Diseases, 2019, , .	0.3	7
276	Comparative evaluation of immunoassays to improve access to diagnosis for Chagas disease in Colombia. International Journal of Infectious Diseases, 2019, 87, 100-108.	3.3	13
277	Longitudinal follow up of serological response in children treated for Chagas disease. PLoS Neglected Tropical Diseases, 2019, 13, e0007668.	3.0	29

#	Article	IF	CITATIONS
278	IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in Bolivia. PLoS Neglected Tropical Diseases, 2019, 13, e0007715.	3.0	6
279	Proposed multidimensional framework for understanding Chagas disease healthcare barriers in the United States. PLoS Neglected Tropical Diseases, 2019, 13, e0007447.	3.0	33
280	Echocardiographic Measurements in a Preclinical Model of Chronic Chagasic Cardiomyopathy in Dogs: Validation and Reproducibility. Frontiers in Cellular and Infection Microbiology, 2019, 9, 332.	3.9	12
281	Elevated IL-17 levels and echocardiographic signs of preserved myocardial function in benznidazole-treated individuals with chronic Chagas' disease. International Journal of Infectious Diseases, 2019, 79, 123-130.	3.3	19
282	American Trypanosomiasis (Chagas Disease). Infectious Disease Clinics of North America, 2019, 33, 119-134.	5.1	145
283	A therapeutic preconceptional vaccine against Chagas disease: A novel indication that could reduce congenital transmission and accelerate vaccine development. PLoS Neglected Tropical Diseases, 2019, 13, e0006985.	3.0	26
284	Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound Selection. Tropical Medicine and Infectious Disease, 2019, 4, 82.	2.3	30
285	Novel chemical starting points for drug discovery in leishmaniasis and Chagas disease. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 10, 58-68.	3.4	12
286	Chagas disease: a report of 17 suspected cases in Japan, 2012–2017. Tropical Medicine and Health, 2019, 47, 38.	2.8	10
287	Case 20-2019: A 52-Year-Old Woman with Fever and Rash after Heart Transplantation. New England Journal of Medicine, 2019, 380, 2564-2573.	27.0	0
288	Antitrypanosomal activity and effect in plasma membrane permeability of (â^')-bornyl p-coumarate isolated from Piper cernuum (Piperaceae). Bioorganic Chemistry, 2019, 89, 103001.	4.1	20
289	A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. PLoS Neglected Tropical Diseases, 2019, 13, e0007413.	3.0	40
290	A retrospective study on the influence of siblings' relatedness in Bolivian patients with chronic Chagas disease. Parasites and Vectors, 2019, 12, 260.	2.5	0
291	Myocarditis in Humans and in Experimental Animal Models. Frontiers in Cardiovascular Medicine, 2019, 6, 64.	2.4	99
292	Current Gaps and Needs for Increasing Access to Healthcare for People with Chagas Disease in the USA. Current Tropical Medicine Reports, 2019, 6, 13-22.	3.7	7
293	Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine, 2019, 37, 3704-3714.	3.8	12
294	T-Cell Immunophenotyping and Cytokine Production Analysis in Patients with Chagas Disease 4 Years after Benznidazole Treatment. Infection and Immunity, 2019, 87, .	2.2	10
295	Antitrypanosomal Activity of Acetogenins Isolated from the Seeds of <i>Porcelia macrocarpa</i> Is Associated with Alterations in Both Plasma Membrane Electric Potential and Mitochondrial Membrane Potential. Journal of Natural Products, 2019, 82, 1177-1182.	3.0	12

#	Article	IF	Citations
296	Fluorescence Proteomic Technology to Analyze Peripheral Blood Mononuclear Cells in Chronic Chagas Disease. Methods in Molecular Biology, 2019, 1955, 363-380.	0.9	0
298	Phenyldihydropyrazolones as Novel Lead Compounds Against <i>Trypanosoma cruzi</i> . ACS Omega, 2019, 4, 6585-6596.	3.5	6
299	Progression of Baseline Electrocardiogram Abnormalities in Chagas Patients Undergoing Antitrypanosomal Treatment. Open Forum Infectious Diseases, 2019, 6, ofz012.	0.9	8
300	Lack of evidence of seronegative infection in an endemic area of Chagas disease. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2019, 61, e11.	1.1	2
301	Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Expert Review of Anti-Infective Therapy, 2019, 17, 145-157.	4.4	77
302	Chagas Cardiomyopathy in Latin America Review. Current Cardiology Reports, 2019, 21, 8.	2.9	28
303	Duration and determinants of Chagas latency. JBI Database of Systematic Reviews and Implementation Reports, 2019, 17, 2122-2128.	1.7	3
304	Redox Balance Keepers and Possible Cell Functions Managed by Redox Homeostasis in Trypanosoma cruzi. Frontiers in Cellular and Infection Microbiology, 2019, 9, 435.	3.9	41
305	MOLECULAR FRACTIONATION WITH CONJUGATE CAPS STUDY OF THE INTERACTION OF THE ANACARDIC ACID WITH THE ACTIVE SITE OF TRYPANOSOMA CRUZI GAPDH ENZYME: A QUANTUM INVESTIGATION. Asian Journal of Pharmaceutical and Clinical Research, 2019, , 183-189.	0.3	1
306	Identification of Trypanosoma cruzi Polyamine Transport Inhibitors by Computational Drug Repurposing. Frontiers in Medicine, 2019, 6, 256.	2.6	7
307	Use of rapid diagnostic tests (RDTs) for conclusive diagnosis of chronic Chagas disease – field implementation in the Bolivian Chaco region. PLoS Neglected Tropical Diseases, 2019, 13, e0007877.	3.0	18
308	Chagas Disease in the United States: a Public Health Approach. Clinical Microbiology Reviews, 2019, 33, .	13.6	151
309	Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of <i>Trypanosoma cruzi</i> infection in mice. Human Vaccines and Immunotherapeutics, 2019, 15, 210-219.	3.3	33
310	Studies of NMR, molecular docking, and molecular dynamics simulation of new promising inhibitors of cruzaine from the parasite Trypanosoma cruzi. Medicinal Chemistry Research, 2019, 28, 246-259.	2.4	15
311	Identification of Triatomines and Their Habitats in a Highly Developed Urban Environment. Vector-Borne and Zoonotic Diseases, 2019, 19, 265-273.	1.5	16
312	Trypanocidal and toxicological assessment in vitro and in silico of three sesquiterpene lactones from Asteraceae plant species. Food and Chemical Toxicology, 2019, 125, 55-61.	3.6	18
313	Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS Infectious Diseases, 2019, 5, 152-157.	3.8	78
314	Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. European Journal of Medicinal Chemistry, 2019, 162, 378-395.	5.5	48

#	Article	IF	CITATIONS
315	Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy. Journal of the American Society of Echocardiography, 2019, 32, 286-295.e3.	2.8	21
316	Ischemic stroke and infectious diseases in low-income and middle-income countries. Current Opinion in Neurology, 2019, 32, 43-48.	3.6	10
317	Ruthenium(II)â€Catalyzed C–H Alkenylation of Quinones: Diversityâ€Oriented Strategy for Trypanocidal Compounds. European Journal of Organic Chemistry, 2019, 2019, 2344-2353.	2.4	25
318	Prevalence of Chagas disease in Colombia: A systematic review and meta-analysis. PLoS ONE, 2019, 14, e0210156.	2.5	37
319	Pathogenesis of Chagas Disease: an Emphasis for Transplant Patient Populations. Current Tropical Medicine Reports, 2019, 6, 1-7.	3.7	2
320	Improved DNA extraction technique from clot for the diagnosis of Chagas disease. PLoS Neglected Tropical Diseases, 2019, 13, e0007024.	3.0	11
321	Trypanothione synthetase confers growth, survival advantage and resistance to anti-protozoal drugs in Trypanosoma cruzi. Free Radical Biology and Medicine, 2019, 130, 23-34.	2.9	19
322	Pathology and Pathogenesis of Chagas Heart Disease. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 421-447.	22.4	166
323	Butenolides from Nectandra oppositifolia (Lauraceae) displayed anti-Trypanosoma cruzi activity via deregulation of mitochondria. Phytomedicine, 2019, 54, 302-307.	5.3	17
324	Trypanosoma cruzi immunoproteome: Calpain-like CAP5.5 differentially detected throughout distinct stages of human Chagas disease cardiomyopathy. Journal of Proteomics, 2019, 194, 179-190.	2.4	12
325	Usefulness of Serial Blood Sampling and PCR Replicates for Treatment Monitoring of Patients with Chronic Chagas Disease. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	29
326	Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of <i>Trypanosoma cruzi </i> chronic infection. Parasitology, 2019, 146, 305-313.	1.5	15
327	Parasitaemia and parasitic load are limited targets of the aetiological treatment to control the progression of cardiac fibrosis and chronic cardiomyopathy in Trypanosoma cruzi-infected dogs. Acta Tropica, 2019, 189, 30-38.	2.0	14
328	Anti–Trypanosoma cruzi effect of the photodynamic antiparasitic chemotherapy using phenothiazine derivatives as photosensitizers. Lasers in Medical Science, 2020, 35, 79-85.	2.1	14
330	Chagas heart disease: A contemporary review. Journal of Nuclear Cardiology, 2020, 27, 445-451.	2.1	18
331	American Trypanosomiasis (Chagas Disease). , 2020, , 762-775.		10
332	Heart Failure in the Developing World. , 2020, , 385-394.e3.		1
333	Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126779.	2.2	6

#	Article	IF	CITATIONS
334	Why hasn't there been more progress in new Chagas disease drug discovery?. Expert Opinion on Drug Discovery, 2020, 15, 145-158.	5.0	44
335	Targeting epimastigotes of Trypanosoma cruzi with a peptide isolated from a phage display random library. Experimental Parasitology, 2020, 210, 107830.	1.2	3
336	Overcoming challenges in the diagnosis and treatment of parasitic infectious diseases in migrants. Expert Review of Anti-Infective Therapy, 2020, 18, 127-143.	4.4	7
337	Induction of Effective Immunity against Trypanosoma cruzi. Infection and Immunity, 2020, 88, .	2.2	9
338	Medical reversals in low―and middleâ€income countries. International Journal of Health Planning and Management, 2020, 35, 631-638.	1.7	1
339	Current trends in the pharmacological management of Chagas disease. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 12, 7-17.	3.4	87
340	Culture, Environment and Health in the Yucatan Peninsula. , 2020, , .		4
341	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents. European Journal of Medicinal Chemistry, 2020, 186, 111877.	5.5	4
342	The unmet medical need for Trypanosoma cruzi-infected patients: Monitoring the disease status. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165628.	3.8	4
343	Clinical, Cardiological and Serologic Follow-Up of Chagas Disease in Children and Adolescents from the Amazon Region, Brazil: Longitudinal Study. Tropical Medicine and Infectious Disease, 2020, 5, 139.	2.3	4
344	Vector competence and feeding-excretion behavior of Triatoma rubrovaria (Blanchard, 1843) (Hemiptera: Reduviidae) infected with Trypanosoma cruzi TcVI. PLoS Neglected Tropical Diseases, 2020, 14, e0008712.	3.0	11
345	Circulating <i>Trypanosoma cruzi</i> load and major cardiovascular outcomes in patients with chronic Chagas cardiomyopathy: a prospective cohort study. Tropical Medicine and International Health, 2020, 25, 1534-1541.	2.3	8
346	Chagas Disease: Current View of an Ancient and Global Chemotherapy Challenge. ACS Infectious Diseases, 2020, 6, 2830-2843.	3.8	17
347	Chagas Disease. , 2020, , .		6
348	Stratification of cardiopathies using photoplethysmographic signals. Informatics in Medicine Unlocked, 2020, 20, 100417.	3.4	1
349	Chagas Disease: Perspectives on the Past and Present and Challenges in Drug Discovery. Molecules, 2020, 25, 5483.	3.8	28
350	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis. Journal of Natural Products, 2020, 83, 3571-3583.	3.0	6
351	A novel Trypanosoma cruzi secreted antigen as a potential biomarker of Chagas disease. Scientific Reports, 2020, 10, 19591.	3.3	4

ARTICLE IF CITATIONS Trypanosomatid-Caused Conditions: State of the Art of Therapeutics and Potential Applications of 352 3.6 9 Lipid-Based Nanocarriers. Frontiers in Chemistry, 2020, 8, 601151. Trypanosoma cruzi Presenilin-Like Transmembrane Aspartyl Protease: Characterization and Cellular 4.0 Localization. Biomolecules, 2020, 10, 1564. Understanding the oral transmission of Trypanosoma cruzi as a veterinary and medical foodborne 354 1.9 24 zoonosis. Research in Veterinary Science, 2020, 132, 448-461. Anticancer and antitrypanosomal activities of trinuclear ruthenium compounds with orthometalated phenazine ligands. Dálton Transactions, 2020, 49, 16440-16452. <i>In Vivo</i> Analysis of Trypanosoma cruzi Persistence Foci at Single-Cell Resolution. MBio, 2020, 11, 356 4.1 40 Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against Trypanosoma cruzi. Frontiers in Immunology, 2020, 11, 565142. 4.8 Targeting L-Proline Uptake as New Strategy for Anti-chagas Drug Development. Frontiers in Chemistry, 358 3.6 3 2020, 8, 696. Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice 359 treated with benznidazole or posaconazole. PLoS Neglected Tropical Diseases, 2020, 14, e0008726. Short-course Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in women of 360 reproductive age (BETTY): a non-inferiority randomized controlled trial study protocol. Reproductive 3.1 16 Health, 2020, 17, 128. Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas 3.1 disease and other aetiologies. ESC Heart Failure, 2020, 7, 3086-3094. Rapid Diagnostic Tests for Trypanosoma cruzi Infection: Field Evaluation of Two Registered Kits in a Region of Endemicity and a Region of Nonendemicity in Argentina. Journal of Clinical Microbiology, 362 3.9 13 2020, 58, . Animal models of Chagas disease and their translational value to drug development. Expert Opinion 5.0 on Drug Discovery, 2020, 15, 1381-1402. Assessing the entomo-epidemiological situation of Chagas disease in rural communities in the state of PiauÅ, Brazilian semi-arid region. Transactions of the Royal Society of Tropical Medicine and Hygiene, 364 1.8 6 2020, 114, 820-829. Dual and Opposite Roles of Reactive Oxygen Species (ROS) in Chagas Disease: Beneficial on the 4.0 Pathogen and Harmful on the Host. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-17. Experimental Nanovaccine Offers Protection Against Repeat Exposures to Trypanosoma cruzi Through 366 10 4.8 Activation of Polyfunctional T Cell Response. Frontiers in Immunology, 2020, 11, 595039. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection). The Cóchrane Library, 2020, 12, CĎ004102. Chagas cardiomyopathy and heart failure: From epidemiology to treatment. Revista Portuguesa De 368 0.2 1 Cardiologia (English Edition), 2020, 39, 279-289. Extent of polymorphism and selection pressure on the <i>Trypanosoma cruzi</i> vaccine candidate 369 3.1 antigen Tc24. Evolutionary Applications, 2020, 13, 2663-2672.

#	Article	IF	CITATIONS
370	Population pharmacokinetics and biodistribution of benznidazole in mice. Journal of Antimicrobial Chemotherapy, 2020, 75, 2213-2221.	3.0	6
371	Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques. Vaccine, 2020, 38, 4584-4591.	3.8	16
372	Chagas disease in the United Kingdom: A review of cases at the Hospital for Tropical Diseases London 1995–2018. The current state of detection of Chagas disease in the UK. Travel Medicine and Infectious Disease, 2020, 36, 101760.	3.0	9
373	Strategies towards potent trypanocidal drugs: Application of Rh-catalyzed [2 + 2 + 2] cycloadditions, sulfonyl phthalide annulation and nitroalkene reactions for the synthesis of substituted quinones and their evaluation against Trypanosoma cruzi. Bioorganic and Medicinal Chemistry, 2020, 28, 115565.	3.0	13
374	Precision Health for Chagas Disease: Integrating Parasite and Host Factors to Predict Outcome of Infection and Response to Therapy. Frontiers in Cellular and Infection Microbiology, 2020, 10, 210.	3.9	23
375	Honokiol attenuates oxidative stress-dependent heart dysfunction in chronic Chagas disease by targeting AMPK / NFE2L2 / SIRT3 signaling pathway. Free Radical Biology and Medicine, 2020, 156, 113-124.	2.9	11
376	Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 13, 107-120.	3.4	8
377	Effect of Posaconazole in an in vitro model of cardiac fibrosis induced by Trypanosoma cruzi. Molecular and Biochemical Parasitology, 2020, 238, 111283.	1.1	5
378	Chagas Disease in the New York City Metropolitan Area. Open Forum Infectious Diseases, 2020, 7, ofaa156.	0.9	11
379	Chagas cardiomyopathy and heart failure: From epidemiology to treatment. Revista Portuguesa De Cardiologia, 2020, 39, 279-289.	0.5	19
380	Challenges in Chagas Disease Drug Development. Molecules, 2020, 25, 2799.	3.8	33
381	Risk Score for Predicting 2â€Year Mortality in Patients With Chagas Cardiomyopathy From Endemic Areas: SaMiâ€Trop Cohort Study. Journal of the American Heart Association, 2020, 9, e014176.	3.7	21
382	Electrochemical Selenation/Cyclization of Quinones: A Rapid, Green and Efficient Access to Functionalized Trypanocidal and Antitumor Compounds. European Journal of Organic Chemistry, 2020, 2020, 4474-4486.	2.4	42
383	The role of fat on cardiomyopathy outcome in mouse models of chronic Trypanosoma cruzi infection. Parasitology Research, 2020, 119, 1829-1843.	1.6	1
384	Potential Role of Antioxidants as Adjunctive Therapy in Chagas Disease. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	4.0	17
385	Synthesis of quinoline derivatives as potential cysteine protease inhibitors. Future Medicinal Chemistry, 2020, 12, 571-581.	2.3	9
386	Disruption of Intracellular Calcium Homeostasis as a Therapeutic Target Against Trypanosoma cruzi. Frontiers in Cellular and Infection Microbiology, 2020, 10, 46.	3.9	44
387	Discovery and Optimization of a Compound Series Active against <i>Trypanosoma cruzi</i> , the Causative Agent of Chagas Disease. Journal of Medicinal Chemistry, 2020, 63, 3066-3089.	6.4	8

#	Article	IF	CITATIONS
388	Under Our Very Eyes. New England Journal of Medicine, 2020, 382, 952-957.	27.0	1
389	TLR4 agonist protects against <i>Trypanosoma cruzi</i> acute lethal infection by decreasing cardiac parasite burdens. Parasite Immunology, 2020, 42, e12769.	1.5	14
390	Repositioning of leishmanicidal [1,2,3]Triazolo[1,5-a]pyridinium salts for Chagas disease treatment: Trypanosoma cruzi cell death involving mitochondrial membrane depolarisation and Fe-SOD inhibition. Parasitology Research, 2020, 119, 2943-2954.	1.6	4
391	Impact of the social context on the prognosis of Chagas disease patients: Multilevel analysis of a Brazilian cohort. PLoS Neglected Tropical Diseases, 2020, 14, e0008399.	3.0	14
392	Chagas Disease Infection Reactivation after Heart Transplant. Tropical Medicine and Infectious Disease, 2020, 5, 106.	2.3	13
393	New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
394	Update on the major imported protozoan infections in travelers and migrants. Future Microbiology, 2020, 15, 213-225.	2.0	18
395	Antigen-Based Nano-Immunotherapy Controls Parasite Persistence, Inflammatory and Oxidative Stress, and Cardiac Fibrosis, the Hallmarks of Chronic Chagas Cardiomyopathy, in A Mouse Model of Trypanosoma cruzi Infection. Vaccines, 2020, 8, 96.	4.4	16
396	Heart failure can affect everyone: the ESC Geoffrey Rose lecture. European Heart Journal, 2020, 41, 1298-1306.	2.2	19
397	Imiquimod-loaded nanoarchaeosomes as a promising immunotherapy against Trypanosoma cruzi infection. Colloids and Surfaces B: Biointerfaces, 2020, 189, 110850.	5.0	6
398	Notch receptor expression in Trypanosoma cruzi â€infected human umbilical vein endothelial cells treated with benznidazole or simvastatin revealed by microarray analysis. Cell Biology International, 2020, 44, 1112-1123.	3.0	2
399	Chagas disease: Historic perspective. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165689.	3.8	21
400	Structureâ€Activity Relationship of Phenylpyrazolones against Trypanosoma cruzi. ChemMedChem, 2020, 15, 1310-1321.	3.2	5
401	Improving the drug-likeness of inspiring natural products - evaluation of the antiparasitic activity against Trypanosoma cruzi through semi-synthetic and simplified analogues of licarin A. Scientific Reports, 2020, 10, 5467.	3.3	23
402	Efficacy of continuous versus intermittent administration of nanoformulated benznidazole during the chronic phase of Trypanosoma cruzi Nicaragua infection in mice. Journal of Antimicrobial Chemotherapy, 2020, 75, 1906-1916.	3.0	10
403	Chagas Disease and Healthcare Rights in the Bolivian Immigrant Community of São Paulo, Brazil. Tropical Medicine and Infectious Disease, 2020, 5, 62.	2.3	6
404	Chagas' heart disease: Descriptive analysis of 141 patients in a hospital of Madrid, Spain. Travel Medicine and Infectious Disease, 2020, 37, 101690.	3.0	5
405	Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II superiority clinical trial. Trials, 2020, 21, 328.	1.6	30

# 406	ARTICLE Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus. PLoS Neglected Tropical Diseases, 2020, 14, e0008035.	IF 3.0	CITATIONS
407	Knocking Down TcNTPDase-1 Gene Reduces in vitro Infectivity of Trypanosoma cruzi. Frontiers in Microbiology, 2020, 11, 434.	3.5	5
408	High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi. Microorganisms, 2020, 8, 472.	3.6	10
409	Perspectives in Chagas Disease Treatment. Global Heart, 2020, 10, 189.	2.3	4
410	Biomarkers and Mortality in Severe Chagas Cardiomyopathy. Global Heart, 2015, 10, 173.	2.3	43
411	Chagas' cardiomyopathy and Lyme carditis: Lessons learned from two infectious diseases affecting the heart. Trends in Cardiovascular Medicine, 2021, 31, 233-239.	4.9	11
412	Evaluation of the effects in cellular membrane models of antitrypanosomal poly-thymolformaldehyde (PTF) using Langmuir monolayers. Biochimica Et Biophysica Acta - Biomembranes, 2021, 1863, 183500.	2.6	3
413	Congenital chagas disease: Development and assessment of a specific IgM capture-based assay for diagnosis of transmission. Acta Tropica, 2021, 213, 105738.	2.0	2
414	Benznidazole for the treatment of Chagas disease. Expert Review of Anti-Infective Therapy, 2021, 19, 547-556.	4.4	25
415	Dual chemotherapy with benznidazole at suboptimal dose plus curcumin nanoparticles mitigates Trypanosoma cruzi-elicited chronic cardiomyopathy. Parasitology International, 2021, 81, 102248.	1.3	12
416	Bioenergetics impairment of Trypanosoma cruzi by the antihypertensive manidipine: A drug repurposing strategy. Acta Tropica, 2021, 214, 105768.	2.0	3
417	Review of pharmacological options for the treatment of Chagas disease. British Journal of Clinical Pharmacology, 2022, 88, 383-402.	2.4	22
418	Survival after heart transplantation for Chagas cardiomyopathy using a conventional protocol: A 10â€year experience in a single center. Transplant Infectious Disease, 2021, 23, e13549.	1.7	4
419	Chagas Disease: Chronic Chagas Cardiomyopathy. Current Problems in Cardiology, 2021, 46, 100507.	2.4	59
420	A Mechanistic Probe into the Dual Inhibition of T. cruzi Glucokinase and Hexokinase in Chagas Disease Treatment – A Stone Killing Two Birds?. Chemistry and Biodiversity, 2021, 18, e2000863.	2.1	1
421	The Case for the Development of a Chagas Disease Vaccine: Why? How? When?. Tropical Medicine and Infectious Disease, 2021, 6, 16.	2.3	17
422	Eco-Epidemiology of Vector-Borne Transmission of Trypanosoma cruzi in Domestic Habitats. True Bugs (Heteroptera) of the Neotropics, 2021, , 447-489.	1.2	11
423	Chagas Disease. Neglected Tropical Diseases, 2021, , 93-115.	0.4	0

ARTICLE

IF CITATIONS

424	Trypanosoma cruzi. , 2021, , .		0
425	Nanomedicines against Chagas disease. , 2021, , 169-189.		2
426	Optimization of 1,4-Naphthoquinone Hit Compound: A Computational, Phenotypic, and In Vivo Screening against Trypanosoma cruzi. Molecules, 2021, 26, 423.	3.8	9
428	Optimization and biological validation of an in vitro assay using the transfected Dm28c/pLacZ Trypanosoma cruzi strain. Biology Methods and Protocols, 2021, 6, bpab004.	2.2	0
429	Memory impairment in chronic experimental Chagas disease: Benznidazole therapy reversed cognitive deficit in association with reduction of parasite load and oxidative stress in the nervous tissue. PLoS ONE, 2021, 16, e0244710.	2.5	14
430	Benznidazole modulates release of inflammatory mediators by cardiac spheroids infected with Trypanosoma cruzi. Experimental Parasitology, 2021, 221, 108061.	1.2	5
431	Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection. Scientific Reports, 2021, 11, 3222.	3.3	20
432	Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole. International Journal of Molecular Sciences, 2021, 22, 1960.	4.1	1
433	Essential oils from Syzygium aromaticum and Zingiber officinale, administered alone or in combination with benznidazole, reduce the parasite load in mice orally inoculated with Trypanosoma cruzi II. BMC Complementary Medicine and Therapies, 2021, 21, 77.	2.7	6
434	Chagas Disease in the United States: A Perspective on Diagnostic Testing Limitations and Next Steps. American Journal of Tropical Medicine and Hygiene, 2021, , .	1.4	7
435	Wnt Signaling Plays a Key Role in the Regulation of the Immune Response and Cardiac Damage during <i>Trypanosoma cruzi</i> Infection. ACS Infectious Diseases, 2021, 7, 566-578.	3.8	2
436	Quo vadis? Central Rules of Pathogen and Disease Tropism. Frontiers in Cellular and Infection Microbiology, 2021, 11, 640987.	3.9	6
437	The Role of Nitro (NO2-), Chloro (Cl), and Fluoro (F) Substitution in the Design of Antileishmanial and Antichagasic Compounds. Current Drug Targets, 2021, 22, 379-398.	2.1	3
438	Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease. International Journal of Molecular Sciences, 2021, 22, 3307.	4.1	28
439	Repeat-Driven Generation of Antigenic Diversity in a Major Human Pathogen,ÂTrypanosoma cruzi. Frontiers in Cellular and Infection Microbiology, 2021, 11, 614665.	3.9	25
440	Anti-Trypanosoma cruzi activity, cytotoxicity and, chemical characterization of extracts from seeds of Lonchocarpus cultratus. Journal of Infection in Developing Countries, 2021, 15, 270-279.	1.2	3
441	An Overview on the Therapeutics of Neglected Infectious Diseases—Leishmaniasis and Chagas Diseases. Frontiers in Chemistry, 2021, 9, 622286.	3.6	58
442	Comparison of Health-Related Quality of Life in Outpatients with Chagas and Matched Non-Chagas Chronic Heart Failure in Colombia: A Cross-Sectional Analysis. American Journal of Tropical Medicine and Hygiene, 2021, 104, 951-958.	1.4	6

#	Article	IF	CITATIONS
443	Advanced Therapies for Ventricular Arrhythmias in Patients With ChagasicÂCardiomyopathy. Journal of the American College of Cardiology, 2021, 77, 1225-1242.	2.8	11
444	Chagas Cardiomyopathy: From Romaña Sign to Heart Failure and Sudden Cardiac Death. Pathogens, 2021, 10, 505.	2.8	13
445	New Approaches for the Treatment of Chagas Disease. Current Drug Targets, 2021, 22, 835-841.	2.1	4
446	Management of Esophageal Dysphagia in Chagas Disease. Dysphagia, 2021, 36, 517-522.	1.8	8
447	Alterations to the Cardiac Metabolome Induced by Chronic <i>T. cruzi</i> Infection Relate to the Degree of Cardiac Pathology. ACS Infectious Diseases, 2021, 7, 1638-1649.	3.8	17
448	The Potent Trypanocidal Effect of LQB303, a Novel Redox-Active Phenyl-Tert-Butyl-Nitrone Derivate That Causes Mitochondrial Collapse in Trypanosoma cruzi. Frontiers in Microbiology, 2021, 12, 617504.	3.5	2
449	Structure Activity Relationship of N-Substituted Phenyldihydropyrazolones Against Trypanosoma cruzi Amastigotes. Frontiers in Chemistry, 2021, 9, 608438.	3.6	1
450	Disagreement between PCR and serological diagnosis of Trypanosoma cruzi infection in blood donors from a Colombian endemic region. Biomedica, 2021, 41, 47-59.	0.7	1
451	An evaluation of nifurtimox for Chagas disease in children. Expert Opinion on Orphan Drugs, 2021, 9, 139-149.	0.8	0
452	New global targets for NTDs in the WHO roadmap 2021–2030. PLoS Neglected Tropical Diseases, 2021, 15, e0009373.	3.0	78
453	Experiences with Diagnosis and Treatment of Chagas Disease at a United States Teaching Hospital—Clinical Features of Patients with Positive Screening Serologic Testing. Tropical Medicine and Infectious Disease, 2021, 6, 93.	2.3	4
455	Library of Selenocyanate and Diselenide Derivatives as In Vivo Antichagasic Compounds Targeting Trypanosoma cruzi Mitochondrion. Pharmaceuticals, 2021, 14, 419.	3.8	10
456	Age-related anomalies of electrocardiograms in patients from areas with differential Seroprevalence of Chagas disease in Southern Bolivia. Parasite Epidemiology and Control, 2021, 13, e00204.	1.8	3
457	Prevalencia de cardiopatÃa chagásica en la miocardiopatÃa dilatada. Archivos De Cardiologia De Mexico, 2021, 91, 50-57.	0.2	5
458	Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection. JCl Insight, 2021, 6, .	5.0	5
459	Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain. Pathogens, 2021, 10, 729.	2.8	3
460	Ruthenium(II)- and Palladium(II)-catalyzed position-divergent C H oxygenations of arylated quinones: Identification of hydroxylated quinonoid compounds with potent trypanocidal activity. Bioorganic and Medicinal Chemistry, 2021, 40, 116164.	3.0	2
461	IgG Subclass Analysis in Patients with Chagas Disease 4ÂYears After Benznidazole Treatment. Acta Parasitologica, 2021, 66, 1499-1509.	1.1	2

#	ARTICLE	IF	CITATIONS
462	Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment. Parasitology, 2021, 148, 1320-1327.	1.5	4
463	T Cell Specificity: A Great Challenge in Chagas Disease. Frontiers in Immunology, 2021, 12, 674078.	4.8	12
464	Risk of Trypanosoma cruzi infection among travellers visiting friends and relatives to continental Latin America. PLoS Neglected Tropical Diseases, 2021, 15, e0009528.	3.0	2
465	A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease. Tropical Medicine and Infectious Disease, 2021, 6, 128.	2.3	8
466	Where was my patient born? The Intersection of tropical medicine and migrant health. Current Opinion in Infectious Diseases, 2021, 34, 447-454.	3.1	3
467	α-Gal immunization positively impacts Trypanosoma cruzi colonization of heart tissue in a mouse model. PLoS Neglected Tropical Diseases, 2021, 15, e0009613.	3.0	7
468	Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 692655.	3.9	9
469	Î³â€Łactones from <i>Persea americana</i> and <i>Persea fulva</i> – <i>in Vitro</i> and <i>in Silico</i> Evaluation of <i>Trypanosoma cruzi</i> Activity. Chemistry and Biodiversity, 2021, 18, e2100362.	2.1	3
470	Disulfiram repurposing in the combined chemotherapy of Chagas disease. Medicine, Case Reports and Study Protocols, 2021, 2, e0110.	0.1	5
471	Computer aided drug discovery review for infectious diseases with case study of anti-Chagas project. Parasitology International, 2021, 83, 102366.	1.3	3
472	Chemical Constituents from Aerial Parts of <i>Baccharis sphenophylla</i> and Effects against Intracellular Forms of <i>Trypanosoma cruzi</i> . Chemistry and Biodiversity, 2021, 18, e2100466.	2.1	3
473	Predictors of development of cardiac and digestive disorders among patients with indeterminate chronic Chagas Disease. PLoS Neglected Tropical Diseases, 2021, 15, e0009680.	3.0	2
475	Melatonin decreases circulating Trypanosoma cruzi load with no effect on tissue parasite replication. Canadian Journal of Physiology and Pharmacology, 2021, 99, 795-802.	1.4	2
476	Signal Transducer and Activator of Transcription-3 Modulation of Cardiac Pathology in Chronic Chagasic Cardiomyopathy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 708325.	3.9	9
477	Oxidative stress implications for therapeutic vaccine development against Chagas disease. Expert Review of Vaccines, 2021, 20, 1395-1406.	4.4	0
478	Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2021, 15, e0009689.	3.0	9
479	In vivo protection against chagasic cardiomyopathy progression using trypanocidal fractions from Lippia alba (Verbenaceae) essential oils. Industrial Crops and Products, 2021, 167, 113553.	5.2	3
480	From Magic Bullet to Magic Bomb: Reductive Bioactivation of Antiparasitic Agents. ACS Infectious Diseases, 2021, 7, 2777-2786.	3.8	14

#	Article	IF	CITATIONS
481	Incidence and Predictors of Progression to Chagas Cardiomyopathy: Long-Term Follow-Up of <i>Trypanosoma cruzi</i> –Seropositive Individuals. Circulation, 2021, 144, 1553-1566.	1.6	18
482	Insight into Recent Drug Discoveries against Trypanosomatids and Plasmodium spp Parasites: New Metal-based Compounds. Current Medicinal Chemistry, 2021, 28, .	2.4	1
484	A Southwestern United States Pilot Investigation of Triatomine–Mite Prevalence. Insects, 2021, 12, 811.	2.2	1
485	Clinical, electrocardiographic and echocardiographic evolution of chronic Chagas disease treated with nifurtimox on prolonged followâ€up in Chile: observational study. Journal of Global Antimicrobial Resistance, 2021, 27, 160-166.	2.2	0
486	Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease. Experimental Parasitology, 2021, 228, 108142.	1.2	6
487	Feasibility of a Combined Mobile-Health Electrocardiographic and Rapid Diagnostic Test Screening for Chagas-Related Cardiac Alterations. Microorganisms, 2021, 9, 1889.	3.6	4
488	Trypanocidal therapy among children infected by Trypanosoma cruzi. Serological and electrocardiographic changes over a mean twenty-five-years follow-up period. Acta Tropica, 2021, 222, 106050.	2.0	3
489	Metabolic flexibility in Trypanosoma cruzi amastigotes: implications for persistence and drug sensitivity. Current Opinion in Microbiology, 2021, 63, 244-249.	5.1	6
490	Advances in the treatment of Chagas disease: Promising new drugs, plants and targets. Biomedicine and Pharmacotherapy, 2021, 142, 112020.	5.6	44
491	Detecting imperative genes and infiltrating immune cells in chronic Chagas cardiomyopathy by bioinformatics analysis. Infection, Genetics and Evolution, 2021, 95, 105079.	2.3	4
492	Inflammatory and Infectious Vasculopathies. , 2022, , 532-547.e7.		0
493	Computational identification of chemical compounds with potential anti-Chagas activity using a classification tree. SAR and QSAR in Environmental Research, 2021, 32, 71-83.	2.2	3
494	Chagas disease reactivation in rheumatologic patients: association with immunosuppressive therapy and humoral response. Clinical Rheumatology, 2021, 40, 2955-2963.	2.2	6
495	HIF-1α and CD73 expression in cardiac leukocytes correlates with the severity of myocarditis in end-stage Chagas disease patients. Journal of Leukocyte Biology, 2021, 109, 233-244.	3.3	6
496	Methods for the Investigation of Trypanosoma cruzi Amastigote Proliferation in Mammalian Host Cells. Methods in Molecular Biology, 2020, 2116, 535-554.	0.9	4
497	Clinical Pharmacology of Drugs for theÂTreatment of Chagas Disease. Birkhauser Advances in Infectious Diseases, 2019, , 299-312.	0.3	2
498	Chagas Disease: An Unknown and Neglected Disease. , 2020, , 1-26.		2
499	Challenges in Chagas Disease Control Through Transmission Routes. , 2020, , 37-55.		1

#	Article	IF	CITATIONS
500	Etiologic Treatment of Chagas Disease: Old Drugs, New Insights, Challenges, and Perspectives. , 2020, , 123-144.		2
501	Trypanocidal treatment of Chagas disease. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 458-470.	0.5	30
502	Phylogeny of the North-Central American clade of blood-sucking reduviid bugs of the tribe Triatomini (Hemiptera: Triatominae) based on the mitochondrial genome. Infection, Genetics and Evolution, 2020, 84, 104373.	2.3	14
503	Chronic Chagas disease: therapeutic protocols and efficacy endpoints. Lancet Infectious Diseases, The, 2018, 18, 719-720.	9.1	1
504	Inflammatory Cardiomyopathy: Case-based Review on Clinical Presentation, Diagnosis, and Management. Cardiology in Review, 2021, 29, 230-237.	1.4	2
505	An unusual case of congestive heart failure in the Netherlands. JMM Case Reports, 2018, 5, e005142.	1.3	3
511	Monocyte glycolysis determines CD8+ T cell functionality in human Chagas disease. JCI Insight, 2019, 4,	5.0	11
512	Insights from quantitative and mathematical modelling on the proposed WHO 2030 goals for Chagas disease. Gates Open Research, 2019, 3, 1539.	1.1	7
513	Changes in Proteome Profile of Peripheral Blood Mononuclear Cells in Chronic Chagas Disease. PLoS Neglected Tropical Diseases, 2016, 10, e0004490.	3.0	22
514	Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease. PLoS Neglected Tropical Diseases, 2016, 10, e0004508.	3.0	39
515	Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade. PLoS Neglected Tropical Diseases, 2016, 10, e0004584.	3.0	57
516	Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study. PLoS Neglected Tropical Diseases, 2016, 10, e0004651.	3.0	13
517	Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses. PLoS Neglected Tropical Diseases, 2016, 10, e0004657.	3.0	32
518	Impact of Helminth Infection on the Clinical and Microbiological Presentation of Chagas Diseases in Chronically Infected Patients. PLoS Neglected Tropical Diseases, 2016, 10, e0004663.	3.0	17
519	Molecular Diagnosis of Chagas Disease in Colombia: Parasitic Loads and Discrete Typing Units in Patients from Acute and Chronic Phases. PLoS Neglected Tropical Diseases, 2016, 10, e0004997.	3.0	56
520	Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram. PLoS Neglected Tropical Diseases, 2017, 11, e0005244.	3.0	34
521	Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis. PLoS Neglected Tropical Diseases, 2017, 11, e0005501.	3.0	50
522	A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients. PLoS Neglected Tropical Diseases, 2018, 12, e0006226.	3.0	32

#	Article	IF	CITATIONS
523	Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico. PLoS Neglected Tropical Diseases, 2018, 12, e0006240.	3.0	31
524	Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069. PLoS Neglected Tropical Diseases, 2020, 14, e0007481.	3.0	17
525	A new patient registry for Chagas disease. PLoS Neglected Tropical Diseases, 2020, 14, e0008418.	3.0	8
526	"We have already heard that the treatment doesn't do anything, so why should we take it?†A mixed method perspective on Chagas disease knowledge, attitudes, prevention, and treatment behaviour in the Bolivian Chaco. PLoS Neglected Tropical Diseases, 2020, 14, e0008752.	3.0	5
527	Early impairment of myocardial deformation assessed by regional speckle-tracking echocardiography in the indeterminate form of Chagas disease without fibrosis detected by cardiac magnetic resonance. PLoS Neglected Tropical Diseases, 2020, 14, e0008795.	3.0	11
528	miRNAs may play a major role in the control of gene expression in key pathobiological processes in Chagas disease cardiomyopathy. PLoS Neglected Tropical Diseases, 2020, 14, e0008889.	3.0	31
529	Chagas Cardiomyopathy: Usefulness of EKG and Echocardiogram in a Non-Endemic Country. PLoS ONE, 2016, 11, e0157597.	2.5	28
530	Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil. PLoS ONE, 2016, 11, e0165950.	2.5	5
531	Resveratrol Reverses Functional Chagas Heart Disease in Mice. PLoS Pathogens, 2016, 12, e1005947.	4.7	64
532	SIRT1-PGC1α-NFκB Pathway of Oxidative and Inflammatory Stress during Trypanosoma cruzi Infection: Benefits of SIRT1-Targeted Therapy in Improving Heart Function in Chagas Disease. PLoS Pathogens, 2016, 12, e1005954.	4.7	77
533	Clinical Practice Guidelines for Chagas Disease: Recent Developments and Future Needs. Revista Da Sociedade Brasileira De Medicina Tropical, 0, 52, .	0.9	3
534	Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas. Revista Da Sociedade Brasileira De Medicina Tropical, 2020, 53, e20190477.	0.9	7
535	Antiparasitic and anti-inflammatory activities of ß-lapachone-derived naphthoimidazoles in experimental acute Trypanosoma cruzi infection. Memorias Do Instituto Oswaldo Cruz, 2020, 115, e190389.	1.6	12
536	Reações adversas ao benzonidazol no tratamento da Doença de Chagas: revisão sistemática de ensaios clÃnicos randomizados e controlados. Cadernos Saude Coletiva, 2019, 27, 354-362.	0.6	1
537	Structural Heart Diseases. , 2017, , 191-208.		4
538	Benznidazole/Poloxamer 407 Solid Dispersion as a New Strategy to Improve the Treatment of Experimental Trypanosoma cruzi Infection. Journal of Parasitology, 2020, 106, 323.	0.7	4
539	The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era. International Cardiovascular Forum Journal, 0, 7, .	1.1	4
540	Drugs for the etiologic treatment of Chagas disease: Myths and Truths. International Cardiovascular Forum Journal, 0, 7, .	1.1	4

#	Article	IF	CITATIONS
541	Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis. Current Medicinal Chemistry, 2019, 26, 4454-4475.	2.4	41
542	The Thiol-polyamine Metabolism of Trypanosoma cruzi: Molecular Targets and Drug Repurposing Strategies. Current Medicinal Chemistry, 2019, 26, 6614-6635.	2.4	22
543	Amino Acid and Polyamine Membrane Transporters in Trypanosoma cruzi: Biological Function and Evaluation as Drug Targets. Current Medicinal Chemistry, 2019, 26, 6636-6651.	2.4	4
544	Bioluminescent:Fluorescent Trypanosoma cruzi Reporter Strains as Tools for Exploring Chagas Disease Pathogenesis and Drug Activity. Current Pharmaceutical Design, 2021, 27, 1733-1740.	1.9	3
545	Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances. Combinatorial Chemistry and High Throughput Screening, 2019, 22, 509-520.	1.1	6
546	A four-step process for building sustainable access to diagnosis and treatment of Chagas disease. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2019, 43, 1.	1.1	7
547	Screening for Trypanosoma cruzi infection in immigrants and refugees: Systematic review and recommendations from the Spanish Society of Infectious Diseases and Clinical Microbiology. Eurosurveillance, 2020, 25, .	7.0	22
548	Current Challenges and Obstacles to Drug Development for Chagas Disease. Drug Designing & Intellectual Properties International Journal, 2018, 2, .	0.4	2
549	Rapid Progressive Chagasic Myocarditis: A Multifactorial Condition. American Journal of Tropical Medicine and Hygiene, 2016, 95, 247-247.	1.4	3
550	The Prevalence of Chagas Disease Among Latin American Immigrants with Pacemakers in Los Angeles, California. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1139-1142.	1.4	16
551	Congenital Chagas Disease in the United States: Cost Savings through Maternal Screening. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1733-1742.	1.4	40
552	Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1477-1481.	1.4	6
553	A Combination of Itraconazole and Amiodarone Is Highly Effective against Trypanosoma cruzi Infection of Human Stem Cell–Derived Cardiomyocytes. American Journal of Tropical Medicine and Hygiene, 2019, 101, 383-391.	1.4	16
554	Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening. American Journal of Tropical Medicine and Hygiene, 2020, 102, 1086-1089.	1.4	17
555	Mudanças no paradigma da conduta clÃnica e terapêutica da doença de Chagas: avanços e perspectivas na busca da integralidade da saúde. Epidemiologia E Servicos De Saude: Revista Do Sistema Unico De Saude Do Brasil, 2016, 25, 1-10.	1.0	5
556	WHF IASC Roadmap on Chagas Disease. Global Heart, 2020, 15, 26.	2.3	75
557	Clutamine metabolism modulates azole susceptibility in Trypanosoma cruzi amastigotes. ELife, 2020, 9, .	6.0	21
558	Prevention and Control of Chagas Disease – An Overview. International STD Research & Reviews, 2018, 7, 1-15.	0.2	4

#	ARTICLE	IF	CITATIONS
559	New Insights Into Blue Light Phototherapy in Experimental Trypanosoma cruzi Infection. Frontiers in Cellular and Infection Microbiology, 2021, 11, 673070.	3.9	0
560	Antiprotozoal agents: How have they changed over a decade?. Archiv Der Pharmazie, 2022, 355, e2100338.	4.1	8
561	Chagas disease: Immunology of the disease at a glance. Cytokine and Growth Factor Reviews, 2021, 62, 15-22.	7.2	18
562	New Perspectives for Therapeutic Intervention during the Chronic Phase of Trypanosoma Cruzi Infection. Journal of Immunology and Serum Biology, 2016, 2, 1-2.	0.0	0
563	Management of Ventricular Arrhtyhmias in Nonischemic Cardiomyopathic Syndromes. Cardiovascular Medicine, 2017, , 251-274.	0.0	0
564	13: Essential Oil-Based Nanomedicines against Trypanosomatides. , 2017, , 258-278.		0
565	The Interleukin-17 (IL-17) puzzle in Chagas disease. Journal of Immunology and Serum Biology, 2017, 3, 120-121.	0.0	0
566	The Indeterminate Form of Chagas Disease. Arquivos Brasileiros De Cardiologia, 2018, 110, 111-112.	0.8	4
567	OBSOLETE: Chronic Infections of the Heart. , 2018, , .		0
568	Obstructive Sleep Apnea is Common and Associated with Heart Remodeling in Patients with Chagas Disease. Arquivos Brasileiros De Cardiologia, 2018, 111, 364-372.	0.8	1
572	Trypanosoma dionisii as an experimental model to study anti-Trypanosoma cruzi drugs: A comparative analysis with benznidazole, posaconazole and amiodarone. , 2018, 1, 014-023.		0
573	Correlation between the cytokine profile and anticongestive medication in patients with chronic chagasic cardiopathy. Revista Da Sociedade Brasileira De Medicina Tropical, 2019, 52, e20190386.	0.9	1
574	A Panoramic View of theÂlmmune Response to Trypanosoma cruzi Infection. Birkhauser Advances in Infectious Diseases, 2019, , 61-88.	0.3	1
575	Diagnosis of Chagas Disease. Birkhauser Advances in Infectious Diseases, 2019, , 141-158.	0.3	2
576	Heart Failure Awareness Day: A Tribute to the Genius Carlos Chagas. Arquivos Brasileiros De Cardiologia, 2019, 113, 5-8.	0.8	4
578	Clinical Care for Individuals with Chronic Trypanosoma cruzi Infection: Decision-Making in theÂMidst of Uncertainty. Birkhauser Advances in Infectious Diseases, 2019, , 199-224.	0.3	1
580	Determination of Benznidazole in Human Dried Blood Spots by Liquid Chromatography–Mass Spectrometry to Monitor Adherence to Trypanosoma cruzi Infection Treatment in Infants and Children. American Journal of Tropical Medicine and Hygiene, 2019, 101, 116-122.	1.4	2
581	Actualización de la Enfermedad de Chagas desde Atención Primaria. Revista De Investigación Y Educación En Ciencias De La Salud (RIECS), 2019, 4, 29-46.	0.0	0

#	Article	IF	CITATIONS
582	Dynamics of T Cells Repertoire During Trypanosoma cruzi Infection and its Post-Treatment Modulation. Current Medicinal Chemistry, 2019, 26, 6519-6543.	2.4	4
583	Tackling Exposure to Chagas Disease in the Yucatan from a Human Ecology Perspective. , 2020, , 293-309.		1
584	Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds. Current Medicinal Chemistry, 2019, 26, 6672-6686.	2.4	2
587	Combined use of two rapid tests for the conclusive diagnosis of Chagas disease: a systematic scoping review. BMJ Open, 2021, 11, e047825.	1.9	5
588	Mortality risk in chronic Chagas cardiomyopathy: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 5466-5481.	3.1	12
589	Transplantation for Chagas Heart Disease: a Comprehensive Review. Current Transplantation Reports, 2021, 8, 344-350.	2.0	1
590	Chagas Disease Drug Discovery in Latin America—A Mini Review of Antiparasitic Agents Explored Between 2010 and 2021. Frontiers in Chemistry, 2021, 9, 771143.	3.6	7
591	Trypanocidal treatment of Chagas disease. Enfermedades Infecciosas Y Microbiologia Clinica (English) Tj ETQq1	1 0,78431 0.3	4 rgBT /Overl
592	<i>In vitro</i> studies and preclinical evaluation of benznidazole microparticles in the acute <i>Trypanosoma cruzi</i> murine model. Parasitology, 2021, 148, 566-575.	1.5	9
593	Insuficiência cardÃaca grave e rapidamente progressiva em paciente adulto jovem com cardiomiopatia chagásica crônica: desafio diagnóstico e terapêutico. , 2020, 99, 512-518.	0.1	0
594	Grandiflorenic acid isolated from Sphagneticola trilobata against Trypanosoma cruzi: Toxicity, mechanisms of action and immunomodulation. Toxicology in Vitro, 2022, 78, 105267.	2.4	2
595	Chagas disease. , 2020, , 1460-1467.		0
596	Diagnosis of Trypanosoma cruzi Infection: Challenges on Laboratory Tests Development and Applications. , 2020, , 75-94.		2
597	Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2020, 62, e52.	1.1	3
598	Structural Optimization and Biological Activity of Pyrazole Derivatives: Virtual Computational Analysis, Recovery Assay and 3D Culture Model as Potential Predictive Tools of Effectiveness against Trypanosoma cruzi. Molecules, 2021, 26, 6742.	3.8	7
599	Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1480-1486.	1.4	1
600	IL-10-Dependent and -Independent Mechanisms Are Involved in the Cardiac Pathology Modulation Mediated by Fenofibrate in an Experimental Model of Chagas Heart Disease. Frontiers in Immunology, 2020, 11, 572178.	4.8	9
601	Lipid metabolism in Trypanosoma cruzi: A review. Molecular and Biochemical Parasitology, 2020, 240, 111324.	1.1	18

#	Article	IF	CITATIONS
602	Specific Infectious Diseases., 2023,, 51-146.		0
603	Pathogenesis of Chronic Chagas Disease: Macrophages, Mitochondria, and Oxidative Stress. Current Clinical Microbiology Reports, 2018, 5, 45-54.	3.4	31
605	Cardiovascular Complications of Chagas' Disease. , 2022, , 45-60.		0
606	Aspirin-triggered resolvin D1 reduces parasitic cardiac load by decreasing inflammation in a murine model of early chronic Chagas disease. PLoS Neglected Tropical Diseases, 2021, 15, e0009978.	3.0	11
607	Natural-product-inspired design and synthesis of two series of compounds active against Trypanosoma cruzi: Insights into structure–activity relationship, toxicity, and mechanism of action. Bioorganic Chemistry, 2021, 119, 105492.	4.1	1
608	Homology Modeling and Molecular Dynamics Simulations of Trypanosoma cruzi Phosphodiesterase b1. Chemistry and Biodiversity, 2021, , .	2.1	3
609	Molecular and Clinical Aspects of Chronic Manifestations in Chagas Disease: A State-of-the-Art Review. Pathogens, 2021, 10, 1493.	2.8	12
610	Comprehensive analysis of miRNA–mRNA regulatory network and potential drugs in chronic chagasic cardiomyopathy across human and mouse. BMC Medical Genomics, 2021, 14, 283.	1.5	13
611	Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 765879.	3.9	10
612	Impairment of Multiple Mitochondrial Energy Metabolism Pathways in the Heart of Chagas Disease Cardiomyopathy Patients. Frontiers in Immunology, 2021, 12, 755782.	4.8	12
613	Immunomodulation and Antioxidant Activities as Possible Trypanocidal and Cardioprotective Mechanisms of Major Terpenes from Lippia alba Essential Oils in an Experimental Model of Chronic Chagas Disease. Antioxidants, 2021, 10, 1851.	5.1	4
614	The Blockade of Interleukin-2 During the Acute Phase of Trypanosoma cruzi Infection Reveals Its Dominant Regulatory Role. Frontiers in Cellular and Infection Microbiology, 2021, 11, 758273.	3.9	3
615	Aplicación de la topologÃa molecular para la predicción de nuevos compuestos con actividad citotóxica antitripanosomal. Nereis, 2021, , 25-39.	0.1	0
616	Association of HLA-Bâ^—35 and moderate or severe cutaneous reactions secondary to benznidazole treatment in chronic chagas disease. Clinical Microbiology and Infection, 2022, 28, 881.e1-881.e5.	6.0	2
619	Two-dimensional strain derived parameters provide independent predictors of progression to Chagas cardiomyopathy and mortality in patients with Chagas disease. IJC Heart and Vasculature, 2022, 38, 100955.	1.1	3
620	A profile of research on the parasitic trypanosomatids and the diseases they cause. PLoS Neglected Tropical Diseases, 2022, 16, e0010040.	3.0	22
621	Assessment of a combined treatment with a therapeutic vaccine and benznidazole for the Trypanosoma cruzi chronic infection. Acta Tropica, 2022, 229, 106334.	2.0	8
622	C57BL/6 Mice Pretreated With Alpha-Tocopherol Show a Better Outcome of Trypanosoma cruzi Infection With Less Tissue Inflammation and Fibrosis. Frontiers in Immunology, 2022, 13, 833560.	4.8	0

#	Article	IF	CITATIONS
623	Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2022, 64, e4.	1.1	0
625	Severe Cardiomyopathy from Chronic Chagas Disease. American Journal of Medicine, 2022, , .	1.5	0
626	Identification of Leucinostatins from <i>Ophiocordyceps</i> sp. as Antiparasitic Agents against <i>Trypanosoma cruzi</i> . ACS Omega, 2022, 7, 7675-7682.	3.5	3
627	Chagas Disease: Drug Development and Parasite Targets. Topics in Medicinal Chemistry, 2022, , 1.	0.8	5
628	Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection. Microbiology Spectrum, 2022, 10, e0185221.	3.0	4
629	Left ventricular systolic dysfunction predicted by artificial intelligence using the electrocardiogram in Chagas disease patients–The SaMi-Trop cohort. PLoS Neglected Tropical Diseases, 2021, 15, e0009974.	3.0	3
631	New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia. BMJ Open, 2021, 11, e052897.	1.9	14
632	Perspectives for a new drug candidate for Chagas disease therapy. Memorias Do Instituto Oswaldo Cruz, 2022, 117, e220004.	1.6	11
633	Biological Features of Tcm:ÂA New Trypanosoma Cruzi Isolate from Argentina (Dtu V) Displaying Slow Growth, Cardiac Tropism, and Susceptibility to Benznidazole. SSRN Electronic Journal, 0, , .	0.4	0
634	The Current Directions of Searching for Antiparasitic Drugs. Molecules, 2022, 27, 1534.	3.8	10
636	Mitigation of benznidazole toxicity and oxidative stress following ascorbic acid supplementation in an adult traveller with chronic indeterminate Chagas' disease. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	2
637	Antiparasitic treatment with itraconazole and amiodarone in 2 dogs with severe, symptomatic Chagas cardiomyopathy. Journal of Veterinary Internal Medicine, 2022, 36, 1100-1105.	1.6	6
638	Estimating chagas disease prevalence and number of underdiagnosed, and undertreated individuals in Spain. Travel Medicine and Infectious Disease, 2022, 47, 102284.	3.0	19
639	Electrocardiogram abnormalities in chronic Chagas cardiomyopathy correlate with scar mass and left ventricular dysfunction as assessed by cardiac magnetic resonance imaging. Journal of Electrocardiology, 2022, 72, 66-71.	0.9	2
641	Myocardial sympathetic denervation in Chagas' cardiomyopathy: A predictor of deterioration of left ventricular systolic function. Journal of Nuclear Cardiology, 2022, 29, 3177-3178.	2.1	2
642	Chagas heart disease: An overview of diagnosis, manifestations, treatment, and care. World Journal of Cardiology, 2021, 13, 654-675.	1.5	25
643	Advanced management of ventricular arrhythmias in chronic Chagas cardiomyopathy. Heart Rhythm O2, 2021, 2, 807-818.	1.7	1
644	Inflammatory cardiomyopathy of possibly overlapping aetiology: a case posing treatment dilemma and potential association. ESC Heart Failure, 2022, 9, 761-765.	3.1	1

#	Article	IF	CITATIONS
645	Revisiting the History of Chagas Disease: "Live to tell". International Journal of Cardiovascular Sciences, 2021, , .	0.1	0
647	Intracellular Parasites: Kinetoplastids. , 2022, , .		0
648	Prevalence of Chagas Disease and Associated Factors in an Endemic Area of Northeastern Argentina. American Journal of Tropical Medicine and Hygiene, 2022, , .	1.4	0
667	Bioactivity of Novel Pyrazole-Thiazolines Scaffolds against Trypanosoma cruzi: Computational Approaches and 3D Spheroid Model on Drug Discovery for Chagas Disease. Pharmaceutics, 2022, 14, 995.	4.5	3
668	Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis. PLoS Neglected Tropical Diseases, 2022, 16, e0010386.	3.0	13
669	Early identification of patients with Chagas disease at risk of developing cardiomyopathy using 2-D speckle tracking strain. IJC Heart and Vasculature, 2022, 41, 101060.	1.1	0
670	Towards environmental detection of Chagas disease vectors and pathogen. Scientific Reports, 2022, 12,	3.3	3
671	Insights from the use of erythropoietin in experimental Chagas disease. International Journal for Parasitology: Drugs and Drug Resistance, 2022, 19, 65-80.	3.4	2
672	Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. Expert Review of Vaccines, 2022, 21, 1185-1203.	4.4	3
673	Effect of clinician information sessions on diagnostic testing for Chagas disease. PLoS Neglected Tropical Diseases, 2022, 16, e0010524.	3.0	4
674	Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States. Emerging Infectious Diseases, 2022, 28, 1313-1320.	4.3	37
675	Biological features of TcM: A new Trypanosoma cruzi isolate from Argentina classified into TcV lineage. Current Research in Microbial Sciences, 2022, 3, 100152.	2.3	0
676	Critical analysis of Chagas disease treatment in different countries. Memorias Do Instituto Oswaldo Cruz, 0, 117, .	1.6	6
677	CONSOLIDADO DOS ESTUDOS PUBLICADOS PELA COORTE SAMI-TROP COM PACIENTES PORTADORES DE DOENÇA DE CHAGAS. Revista Unimontes CientÃfica, 2022, 24, 1-28.	0.0	0
678	Call for Consensus in the Evaluation of Circulating Matrix Metalloproteinases in Chagas Disease. American Journal of Tropical Medicine and Hygiene, 2022, , .	1.4	0
679	Geospatial analysis as a tool to identify target areas for Chagas disease education for healthcare providers. BMC Infectious Diseases, 2022, 22, .	2.9	0
680	Cellular Stress and Senescence Induction during Trypanosoma cruzi Infection. Tropical Medicine and Infectious Disease, 2022, 7, 129.	2.3	2
681	New Therapeutics for Chagas Disease: Charting a Course to Drug Approval. , 0, , .		2

#	Article	IF	CITATIONS
682	Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas. Research and Reports in Tropical Medicine, 0, Volume 13, 25-40.	1.4	9
683	Single-Cell Mass Spectrometry Enables Insight into Heterogeneity in Infectious Disease. Analytical Chemistry, 2022, 94, 10567-10572.	6.5	16
684	Chronic Chagas Disease—the Potential Role of Reinfections in Cardiomyopathy Pathogenesis. Current Heart Failure Reports, 2022, 19, 279-289.	3.3	5
685	Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in Trypanosoma cruzi-infected cardiac cells. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	3
687	In vitro interaction of polyethylene glycol-block-poly(D,L-lactide) nanocapsule devices with host cardiomyoblasts and Trypanosoma cruzi-infective forms. Parasitology Research, 2022, 121, 2861-2874.	1.6	2
688	Trypanosoma cruzi parasitemia in chronic Chagas disease: Insights from hierarchical modeling. PLoS Neglected Tropical Diseases, 2022, 16, e0010612.	3.0	2
689	Epigenetic regulation of transcription factor binding motifs promotes Th1 response in Chagas disease cardiomyopathy. Frontiers in Immunology, 0, 13, .	4.8	5
690	Transplantation for chagas' disease: closing the knowledge gap. Current Opinion in Infectious Diseases, 2022, 35, 397-403.	3.1	3
691	A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease. Clinical Infectious Diseases, 2023, 76, e1186-e1194.	5.8	17
692	Anti-trypanosomatid drug discovery: progress and challenges. Nature Reviews Microbiology, 2023, 21, 35-50.	28.6	52
693	Understanding the widespread use of veterinary ivermectin for Chagas disease, underlying factors and implications for the COVID-19 pandemic: a convergent mixed-methods study. BMJ Open, 2022, 12, e058572.	1.9	0
694	TREATMENT OF CHAGAS DISEASE: AN INTEGRATIVE REVIE. , 2022, , 10-24.		Ο
695	Comparison of 1-year healthcare resource utilization and related costs for patients with heart failure in the Chagas and non-Chagas matched cohorts. Therapeutic Advances in Infectious Disease, 2022, 9, 204993612211142.	1.8	0
696	Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice. PLoS Neglected Tropical Diseases, 2022, 16, e0010258.	3.0	8
697	Blood DNA methylation marks discriminate Chagas cardiomyopathy disease clinical forms. Frontiers in Immunology, 0, 13, .	4.8	0
698	Metabolomic Profiling of End-Stage Heart Failure Secondary to Chronic Chagas Cardiomyopathy. International Journal of Molecular Sciences, 2022, 23, 10456.	4.1	4
699	Chagas' disease: the hidden enemy around the world. The Lancet Regional Health - Western Pacific, 2023, 31, 100605.	2.9	1
700	Kinetic Characterization and Inhibition of <i>Trypanosoma cruzi</i> Hypoxanthine–Guanine Phosphoribosyltransferases. Biochemistry, 2022, 61, 2088-2105.	2.5	8

ARTICLE IF CITATIONS Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical 701 3.9 3 diseases?. Frontiers in Cellular and Infection Microbiology, 0, 12, . Safety and preservation of cardiac function following therapeutic vaccination against Trypanosoma 3.1 cruzi in rhesus macaques. Journal of Microbiology, Immunology and Infection, 2023, 56, 400-407. Platelets, Macrophages, and Thromboinflammation in Chagas Disease. Journal of Inflammation 703 3.5 0 Research, 0, Volume 15, 5689-5706. Successful treatment of suspected early form of chronic Chagas cardiomyopathy: a case report. 704 European Heart Journal - Case Reports, 2022, 6, . Genome-wide association study for Chagas Cardiomyopathy identify a new risk locus on chromosome 18 associated with an immune-related protein and transcriptional signature. PLoS Neglected Tropical 705 3.0 1 Diseases, 2022, 16, e0010725. Drug Repurposing in Chagas Disease: Chloroquine Potentiates Benznidazole Activity against Trypanosoma cruzi <i>In Vitro</i> and <i>In Vivo</i>. Antimicrobial Agents and Chemotherapy, 2022, 66, 3.2 Treatment of Chronic Chagasic Patients: Is Killing the Parasite the Only Option?. EMJ Cardiology, 0, , 707 0.0 0 100-111. Avoiding clinical trial failures in neglected tropical diseases: The example of Chagas disease. Clinical 708 5.8 Infectious Diseases, 0, , . 709 Antiparasitic Agents., 2023, , 1598-1617.e2. 1 Sustained monomorphic ventricular tachycardia as the presenting sign of Chagas' cardiomyopathy in a low prevalence setting, diagnosis and management challenges. A case report. Therapeutic Advances in Infectious Disease, 2022, 9, 204993612211417. 1.8 Overexpression of TcNTPDase-1 Gene Increases Infectivity in Mice Infected with Trypanosoma cruzi. 711 0 4.1 International Journal of Molecular Sciences, 2022, 23, 14661. Human Trypanosoma cruzi chronic infection leads to individual level steady-state parasitemia: Implications for drug-trial optimization in Chagas disease. PLoS Neglected Tropical Diseases, 2022, 16, 3.0 e0010828. Chagas Heart Disease: Beyond a Single Complication, from Asymptomatic Disease to Heart Failure. 713 2.4 4 Journal of Clinical Medicine, 2022, 11, 7262. Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study. PLoS Neglected Tropical Diseases, 2022, 16, e0010968. Effect of statins on inflammation and cardiac function in patients with chronic Chagas disease: A protocol for pathophysiological studies in a multicenter, placebo-controlled, proof-of-concept phase 716 2 2.5İl trial. PLoS ONE, 2023, 18, e0280335. Trypanosoma cruzi-specific CD8+ T cells and other immunological hallmarks in chronic Chagas 3.9 cardiomyopathy: Two decades of research. Frontiers in Cellular and Infection Microbiology, 0, 12, . Novel Diarylthioether Compounds as Agents for the Treatment of Chagas Disease. Journal of 718 6.4 0 Medicinal Chemistry, 2023, 66, 1522-1542. Statins change the cytokine profile in Trypanosoma cruzi-infected U937 macrophages and murine 719 4.8 cardiac tissue through Rho-associated kinases inhibition. Frontiers in Immunology, 0, 13, .

<u> </u>			-			
Спт	ΆΤΙ	ON	l K	FΡ	OR1	Г

#	Article	IF	CITATIONS
720	Anti-Trypanosoma cruzi antibody profiling in patients with Chagas disease treated with benznidazole assessed by genome phage display. PLoS Neglected Tropical Diseases, 2023, 17, e0011019.	3.0	2
721	Nutritional Heart Disease andÂCardiomyopathies. Journal of the American College of Cardiology, 2023, 81, 187-202.	2.8	4
722	Coupling ELISA to smartphones for POCT of chronic and congenital Chagas disease. Talanta, 2023, 256, 124246.	5.5	3
723	Axl receptor induces efferocytosis, dampens M1 macrophage responses and promotes heart pathology in Trypanosoma cruzi infection. Communications Biology, 2022, 5, .	4.4	6
724	Comparative Genomics and the Improved Diagnosis of Trypanosomiasis and Visceral Leishmaniasis. , 2019, , 186-211.		0
725	Enzymatic synthesis of amlodipine amides and evaluation of their anti- <i>Trypanosoma cruzi</i> activity. Organic and Biomolecular Chemistry, 0, , .	2.8	0
727	Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an <i>In Vivo</i> Model of <i>Trypanosoma cruzi</i> Infection. Journal of Medicinal Chemistry, 2023, 66, 1221-1238.	6.4	1
728	Green microalgae as a potential source of trypanocide compounds. Natural Product Research, 0, , 1-7.	1.8	2
730	Differential pulse voltammetric determination of benznidazole loaded in nanostructured lipid carriers and urine. Electroanalysis, 0, , .	2.9	0
731	Random intercept hierarchical linear model for multi-regional clinical trials. Journal of Biopharmaceutical Statistics, 2024, 34, 16-36.	0.8	0
732	Screening the Pathogen Box to Discover and Characterize New Cruzain and TbrCatL Inhibitors. Pathogens, 2023, 12, 251.	2.8	4
733	A Review on the Immunological Response against Trypanosoma cruzi. Pathogens, 2023, 12, 282.	2.8	11
734	Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	5
735	Chagas Disease. Annals of Internal Medicine, 2023, 176, ITC17-ITC32.	3.9	7
736	Anti-Trypanosoma cruzi Properties of Sesquiterpene Lactones Isolated from Stevia spp.: In Vitro and In Silico Studies. Pharmaceutics, 2023, 15, 647.	4.5	3
737	Experimental and Computational Study of Aryl-thiosemicarbazones Inhibiting Cruzain Reveals Reversible Inhibition and a Stepwise Mechanism. Journal of Chemical Information and Modeling, 2023, 63, 1506-1520.	5.4	2
738	Risk Factors for Progression to Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis. American Journal of Tropical Medicine and Hygiene, 2023, 108, 791-800.	1.4	5
739	Protective effects of Theracurmin treatment during experimental infection of the Colombian strain of Trypanosoma cruzi at the testicular site. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	0

#	Article	IF	CITATIONS
740	Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy. PLoS Neglected Tropical Diseases, 2023, 17, e0011223.	3.0	4
741	Antimicrobial Peptides (AMPs): Potential Therapeutic Strategy against Trypanosomiases?. Biomolecules, 2023, 13, 599.	4.0	2
742	A comprehensive review on potential candidates for the treatment of chagas disease. Chemical Biology and Drug Design, 2023, 102, 587-605.	3.2	1
743	Parasites in the nervous system of dogs and cats. , 2023, , 113-139.		0
744	Piperazine amides with desirable solubility, physicochemical and drug-like properties: Synthesis and evaluation of the anti-Trypanosoma cruzi activity. Saudi Pharmaceutical Journal, 2023, 31, 1265-1273.	2.7	1
746	The evolution of electrocardiographic abnormalities in the elderly with Chagas disease during 14 years of follow-up: The Bambui Cohort Study of Aging. PLoS Neglected Tropical Diseases, 2023, 17, e0011419.	3.0	1
747	WHF Recommendations for the Use of Echocardiography in Chagas Disease. Global Heart, 2023, 18, .	2.3	3
748	Biomarkers and Echocardiographic Predictors of Cardiovascular Outcome in Patients With Chronic Chagas Disease. Journal of the American Heart Association, 2023, 12, .	3.7	2
749	Myocarditis: Etiology, Pathogenesis, and Their Implications in Clinical Practice. Biology, 2023, 12, 874.	2.8	4
750	Experimental Trypanosoma cruzi Infection and Chagas Disease—A Word of Caution. Microorganisms, 2023, 11, 1613.	3.6	0
751	Diretriz da SBC sobre Diagnóstico e Tratamento de Pacientes com Cardiomiopatia da Doença de Chagas – 2023. Arquivos Brasileiros De Cardiologia, 2023, 120, .	0.8	4
752	The need for bilateral collaborations between the Global North and Global South to mitigate parasitic disease burden in the United States. International Journal of Academic Medicine, 2023, 9, 35.	0.2	0
753	Newly Approved Anti-parasitic Drugs for Malaria, Fascioliasis, Onchocerciasis, Chagas Disease, and African Trypanosomiasis. , 2023, , 143-158.		0
754	Simplifying screening for Trypanosoma cruzi in pregnant persons and their infants. PLoS Neglected Tropical Diseases, 2023, 17, e0011329.	3.0	0
755	Screening for Chagas disease from the electrocardiogram using a deep neural network. PLoS Neglected Tropical Diseases, 2023, 17, e0011118.	3.0	0
756	Repurposing of rabeprazole as an anti- <i>Trypanosoma cruzi</i> drug that targets cellular triosephosphate isomerase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, .	5.2	1
757	Kinetic and Structural Characterization of <i>Trypanosoma cruzi</i> Hypoxanthine–Guanine–Xanthine Phosphoribosyltransferases and Repurposing of Transition-State Analogue Inhibitors. Biochemistry, 2023, 62, 2182-2201.	2.5	0
758	Advances in Clinical Practice, Diagnosis and Treatment of Chronic Chagas' Heart Disease. , 2023, 3, .		0

#	Article	IF	CITATIONS
759	Characterization of Latin American migrants at risk for Trypanosoma cruzi infection in a non-endemic setting. Insights into initial evaluation of cardiac and digestive involvement. PLoS Neglected Tropical Diseases, 2023, 17, e0011330.	3.0	2
760	Diagnosis and management of complicated urogenital schistosomiasis: a systematic review of the literature. Infection, 2023, 51, 1185-1221.	4.7	1
761	Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ T-cells. Current Research in Immunology, 2023, 4, 100066.	2.8	2
762	Trypanosoma cruzi Secreted Cyclophilin TcCyP19 as an Early Marker for Trypanocidal Treatment Efficiency. International Journal of Molecular Sciences, 2023, 24, 11875.	4.1	1
763	<i>Trypanosoma cruzi</i> Reactivation After Chimeric Antigen Receptor T-Cell Therapy. Open Forum Infectious Diseases, 2024, 11, .	0.9	1
764	Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies. Beilstein Journal of Nanotechnology, 0, 14, 804-818.	2.8	1
765	American Trypanosomiasis: Chagas Disease. , 2024, , 636-645.		0
766	Immunopathogenesis in Trypanosoma cruzi infection: a role for suppressed macrophages and apoptotic cells. Frontiers in Immunology, 0, 14, .	4.8	2
768	Intra-host <i>Trypanosoma cruzi</i> strain dynamics shape disease progression: the missing link in Chagas disease pathogenesis. Microbiology Spectrum, 2023, 11, .	3.0	1
769	Immunomodulatory proteins from hookworms reduce cardiac inflammation and modulate regulatory responses in a mouse model of chronic Trypanosoma cruzi infection. , 0, 2, .		0
770	Antitrypanosomal Activity of 1,2,3-Triazole-Based Hybrids Evaluated Using In Vitro Preclinical Translational Models. Biology, 2023, 12, 1222.	2.8	0
771	Use of PET/CT to detect myocardial inflammation and the risk of malignant arrhythmia in chronic Chagas disease. Journal of Nuclear Cardiology, 2023, 30, 2702-2711.	2.1	0
772	Seroepidemiological Survey of Chronic Chagas Disease in a Rural Community in Southern Bahia, Brazil, Using Recombinant Chimeric Antigens. Pathogens, 2023, 12, 1222.	2.8	0
773	Stateâ€ofâ€theâ€art document on optimal contemporary management of cardiomyopathies. European Journal of Heart Failure, 2023, 25, 1899-1922.	7.1	2
774	Identifying inhibitors of Trypanosoma cruzi nucleoside diphosphate kinase 1 as potential repurposed drugs for Chagas' disease. Biochemical Pharmacology, 2023, 216, 115766.	4.4	0
775	Parasitemia and antibody response to benznidazole treatment in a cohort of patients with chronic Chagas disease. , 0, 2, .		0
776	Unveiling challenges in real-time PCR strategies for detecting treatment failure: observations from clinical trials on chronic Chagas disease. , 0, 2, .		0
778	An end is in sight: a perspective on PCR as an endpoint for Chagas disease treatment trials. , 0, 2, .		0

		15	0
#	ARTICLE	IF	CITATIONS
779	Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease. Nature Communications, 2023, 14, .	12.8	2
780	Synthesis of new non-natural l-glycosidic flavonoid derivatives and their evaluation as inhibitors of Trypanosoma cruzi ecto-nucleoside triphosphate diphosphohydrolase 1 (TcNTPDase1). Purinergic Signalling, 0, , .	2.2	0
781	Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice. PLoS Pathogens, 2023, 19, e1011627.	4.7	1
782	Persistent Biofluid Small-Molecule Alterations Induced by <i>Trypanosoma cruzi</i> Infection Are Not Restored by Parasite Elimination. ACS Infectious Diseases, 2023, 9, 2173-2189.	3.8	2
784	Mitochondrial DNA Haplogroups and Variants Predispose to Chagas Disease Cardiomyopathy. Hearts, 2023, 4, 97-117.	0.9	0
785	Trypanocidal activity of liposomal isotretinoin and loratadine formulations. Journal of Drug Delivery Science and Technology, 2024, 91, 105241.	3.0	0
786	Clinical trials for Chagas disease: etiological and pathophysiological treatment. Frontiers in Microbiology, 0, 14, .	3.5	0
787	Fifteen Years after the Definition of Trypanosoma cruzi DTUs: What Have We Learned?. Life, 2023, 13, 2339.	2.4	Ο
788	Short-course combination treatment for experimental chronic Chagas disease. Science Translational Medicine, 2023, 15, .	12.4	2
789	Assessment of biomarkers and clinical parameters as predictors of survival in patients with chagasic heart failure. PLoS Neglected Tropical Diseases, 2023, 17, e0011847.	3.0	Ο
790	Evaluation of parasitemia by qPCR in patients with chronic Chagas disease treated with benznidazole. Asian Pacific Journal of Tropical Medicine, 2023, 16, 565-572.	0.8	0
791	Evaluation of Anti-Trypanosoma cruzi Activity of Chemical Constituents from Baccharis sphenophylla Isolated Using High-Performance Countercurrent Chromatography. Molecules, 2024, 29, 212.	3.8	0
792	Biosynthesis of ergosterol as a relevant molecular target of metal-based antiparasitic and antifungal compounds. Coordination Chemistry Reviews, 2024, 503, 215608.	18.8	0
794	Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trial. Lancet Infectious Diseases, The, 2024, 24, 386-394.	9.1	1
795	Shorter treatment in chronic Chagas disease: a new promise?. Lancet Infectious Diseases, The, 2024, 24, 333-334.	9.1	0
796	Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease. Frontiers in Immunology, 0, 14, .	4.8	0
797	Editorial: Early events during host cell-pathogen interaction, volume II. Frontiers in Cellular and Infection Microbiology, 0, 14, .	3.9	0
798	Chagas cardiomyopathy in Boston, Massachusetts: Identifying disease and improving management after community and hospital-based screening. PLoS Neglected Tropical Diseases, 2024, 18, e0011913.	3.0	0

#	Article	IF	CITATIONS
799	The intersection of host <i>in vivo</i> metabolism and immune responses to infection with kinetoplastid and apicomplexan parasites. Microbiology and Molecular Biology Reviews, 2024, 88, .	6.6	0
800	Prevalence of clinical forms of Chagas disease: a systematic review and meta-analysis – data from the RAISE study. The Lancet Regional Health Americas, 2024, 30, 100681.	2.6	0
801	Original algorithms for the detection of cardiovascular involvement of neglected tropical diseases. Expert Review of Cardiovascular Therapy, 2024, 22, 59-74.	1.5	0
802	A Case of Chagas Cardiomyopathy in Western Virginia: Worlds Away?. Cureus, 2023, , .	0.5	0
803	The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis. Pharmaceutics, 2024, 16, 227.	4.5	0
804	Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi/HIV coinfection. PLoS Neglected Tropical Diseases, 2024, 18, e0011961.	3.0	0
805	Exploring the latency period in Chagas disease: duration and determinants in a cohort from Colombia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 0, , .	1.8	0
806	Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy. Experimental Biology and Medicine, 2023, 248, 2062-2071.	2.4	0
807	Trypanocidal and Anti-Inflammatory Effects of Three ent-Kaurane Diterpenoids from Gymnocoronis spilanthoides var. subcordata (Asteraceae). Pharmaceutics, 2024, 16, 415.	4.5	0